DK2389372T3 - Sammensætninger og fremgangsmåder til hæmning af jak-reaktionsvejen - Google Patents

Sammensætninger og fremgangsmåder til hæmning af jak-reaktionsvejen Download PDF

Info

Publication number
DK2389372T3
DK2389372T3 DK10701189.2T DK10701189T DK2389372T3 DK 2389372 T3 DK2389372 T3 DK 2389372T3 DK 10701189 T DK10701189 T DK 10701189T DK 2389372 T3 DK2389372 T3 DK 2389372T3
Authority
DK
Denmark
Prior art keywords
methyl
ylamino
oxo
oxazol
benzo
Prior art date
Application number
DK10701189.2T
Other languages
English (en)
Inventor
Hui Li
Thilo J Heckrodt
Darren John Mcmurtrie
Vanessa Taylor
Rajinder Singh
Pingyu Ding
Rose Yen
Yan Chen
Sambaiah Thota
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42091548&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2389372(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Application granted granted Critical
Publication of DK2389372T3 publication Critical patent/DK2389372T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Dental Preparations (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Claims (19)

1. Forbindelse med formel I:
I eller et salt deraf, hvor: X og Y hver for sig er 0, S, S (0), SO2 eller NR1; hvert R1 uafhængigt for hver forekomst er H, eventuelt substitueret Ci_6alkyl, C (0)-Ci_6alkyl, C02-Ci_6alkyl eller R50; hvert R50 er C(R9)2-0-R10 eller C (R9) 2-S-R10; hvert R9 uafhængigt for hver forekomst er H, eventuelt substitueret Ci-galkyl, eventuelt substitueret Cg-ioaryl eller eventuelt substitueret C7_igarylalkyl; eller alternativt to R9 sammen med carbonatomet, hvortil de er bundet, danner en eventuelt substitueret C3_8cycloalkylgruppe eller en eventuelt substitueret 3-8-leddet heteroalicyclyl; R10 er Ra eller P (0) (0R11)2; hvert R11 uafhængigt for hver forekomst er Ra eller en monovalent kationisk gruppe; eller to R11 sammen med atomerne, hvortil de er bundet, danner en 4-8-leddet cyklisk phosphatgruppe, eller to R11 sammen er en divalent kationisk gruppe; ring A er en Cg-ioaryl eller en 5-10-leddet heteroaryl; hvert R2 uafhængigt for hver forekomst er H, Re, Rb, Re substitueret med et eller flere af de samme eller forskellige Ra og/eller Rb, -0Re substitueret med et eller flere af de samme eller forskellige Ra og/eller Rb, -SRe substitueret med et eller flere af de samme eller forskellige Ra og/eller Rb, -C(0)Re substitueret med et eller flere af de samme eller forskellige Ra og/eller Rb, -N(Ra)Re, hvor Re er substitueret med et eller flere af de samme eller forskellige Ra og/eller Rb, -S(0)2Re substitueret med et eller flere af de samme eller forskellige Ra og/eller Rb, -B(0Ra)2, -B(N(RC)2)2, - (C (Ra) 2) m-Rb, -0-(C(Ra)2)m-Rb, -S - (C (Ra) 2) m-Rb, -0-(C(Rb)2)m-Ra, -N (Ra) - (C (Ra) 2) m-Rb, -0- (CH2)m-CH( (CH2)mRb)Rb, -C (0) N (Ra) - (C (Ra) 2) m-Rb, -0-(C(Ra)2)m-C(0)N(Ra) - (C (Ra) 2) m_Rb, -N ( (C (Ra) 2 ) mRb) 2, -S- (C(Ra)2)m- C (0) N (Ra) - (C (Ra) 2) m-Rb, -N(Ra)-C(0)-N(Ra)-(C(Ra)2)m-Rb, -N (Ra) - C(0)-(C(Ra)2)m-C(Ra) (Rb)2 eller -N (Ra) - (C (Ra) 2) m-C (0) -N (Ra) -(C (Ra) 2) m-Rb; hvert Ra uafhængigt for hver forekomst er H, deuterium, C3-6alkyl, C3-8cycloalkyl, C4-ncycloalkylalkyl, C6-ioaryl, C7- i6arylalkyl, 2-6-leddet heteroalkyl, 3-10-leddet heteroalicyclyl, 4-11-leddet heteroalicyclylalkyl, 5-15-leddet heteroaryl eller 6-16-leddet heteroarylalkyl; hvert Rb uafhængigt for hver forekomst er =0, -0Ra, -0- (C (Ra) 2)m; -0Ra, halogenCi-3alkyloxy, =S, -SRa, =NRa, =N0Ra, - N(Rc)2, halogen, -CF3, -CN, -NC, -OCN, -SCN, -NO, -N02, =N2, - N3, -S (0) Ra, -S (0) 2Ra, -S03Ra, -S(0)N(Rc)2, -0S(0)Ra, -0S(0)2Ra, -0S03Ra, -OS (0) 2N (Rc) 2, -C (0) Ra, -C02Ra, -C(0)N(Rc)2, -C (NRa) - N(Rc)2, -C(N0H)-Ra, -C (NOH)-N (Rc) 2, -0C(0)Ra, -0C (0) 0Ra, 0C(0)N(Rc)2, -0C (NH)-N (R°) 2, -0C (NRa)-N (R°) 2, - [N (Ra) C (0) ] nRa, - [N (Ra) C (0) ] n0Ra, - [N(Ra)C(0) ]nN(Rc)2 eller - [N (Ra) C (NRa) ] n-N (Rc) 2; hvert Rc uafhængigt for hver forekomst er Ra, eller alternativt to Rc sammen med nitrogenatomet, hvortil de er bundet, danner en 3-10-leddet heteroalicyclyl eller en 5-10-leddet heteroaryl, der eventuelt kan inkludere et eller flere af det samme eller forskellige yderligere heteroatomer, og som eventuelt er substitueret med et eller flere af det samme eller forskellige Ra- og/eller Rd-grupper; hvert Rd er =0, -0Ra, halogenCi_3alkyloxy, Ci_6alkyl, =S, -SRa, =NRa, =N0Ra, -N (Ra) 2t halogen, -CF3, -CN, -NC, -OCN, -SCN, -NO, -NO2, =N2, -N3, -S (0) Ra, -S (02) Ra, -S03Ra, -S(0)N(Ra)2, S (0) 2N (Ra) 2, -OS (0) Ra, -OS (0) 2Ra, -0S03Ra, -OS (0) 2N (Ra) 2, -C(0)Ra, -C02Ra, -C (0) N (Ra) 2r -C (NRa)N (Ra) 2, -C(N0H)Ra, -C (NOH) N (Ra) 2, - 0C02Ra, -0C(0)N(Ra)2, -0C (NRa) N (Ra) 2' - [N (Ra) C (0) ] nRa, - (C (Ra) 2) n- 0Ra, -N (Ra)-S (0) 2Ra, -C (0) -Ci-ehalogenalkyl, -S(0)2Ci_ 6ha logenal kyl, -0C(0)Ra, -0 (C (Ra) 2) m_0Ra, -S (C (Ra) 2) m_0Ra, N (Ra) Ci-ehalogenalkyl, -P(0)(0Ra)2, -N (Ra) - (C (Ra) 2) m_0Ra, [N (Ra) C (0) ] n0Ra, - [N(Ra)C(0) ]nN(Ra)2, - [N (Ra) C (NRa) ] n (Ra) 2 eller - N (Ra) C (0) Ci-6halogenalkyl; eller to Rd sammen med atomet eller atomerne, hvortil de er bundet, danner en 3-10-leddet, delvist eller helt mættet, mono- eller bicyklisk ring, der eventuelt indeholder et eller flere heteroatomer og eventuelt er substitueret med et eller flere Ra; hvert Re uafhængigt for hver forekomst er Ci-6alkyl, C3-scycloalkyl, C4-ncycloalkylalkyl, C6-ioaryl, C7_i6arylalkyl, 2-6- leddet heteroalkyl, 3-10-leddet heteroalicyclyl, 4-11-leddet heteroalicyclylalkyl, 5-15-leddet heteroaryl eller 6-16-leddet heteroarylalkyl; p er 0, 1, 2, 3 eller 4; hvert m er 1, 2 eller 3; hvert n er 0, 1, 2 eller 3; eller to R2-grupper sammen med atomet eller atomerne, hvortil de er bundet, danner en 4-10-leddet, delvist eller helt mættet, mono- eller bicyklisk ring, der eventuelt indeholder et eller flere heteroatomer og eventuelt er substitueret med et eller flere Ra og/eller Rb; Z1 og Z2 hver for sig er CH, CR2 eller N; R3 er H, eventuelt substitueret Ci_6alkyl eller R50; R4 er H, eventuelt substitueret Ci_6alkyl eller R50; og R5 er halogen, -CN, eventuelt substitueret Ci_6alkyl, alkynyl, hydroxy, eventuelt substitueret Ci_6alkoxy, nitro, -N(Ra)2, C (O) N (Ra) 2, -C02Ra eller -C(0)Ra.
2. Forbindelse ifølge krav 1 med formel IA eller IB:
IA
IB hvor i formel IA: X og Y hver for sig er O eller NR1; hvert R1 er H, eventuelt substitueret Ci_6alkyl eller R50; hver af R2a, R2b, R2c og R2d uafhængigt for hver forekomst er som defineret for R2; og R5 er halogen, -CN, eventuelt substitueret Ci_6alkyl, nitro, -N(Ra)2, -C(0)N(Ra)2, -C02Ra eller -C(0)Ra. fortrinsvis hvor den ene af X og Y er O, og den anden er NR1; og i formel IB: Q1 og Q2 hver for sig er N eller CH, forudsat at mindst den ene af Q1 og Q2 er N; X og Y hver for sig er 0 eller NR1; hvert R1 uafhængigt for hver forekomst er H, eventuelt substitueret Ci_6alkyl eller R50; p er 0, 1, 2 eller 3; og R5 er halogen, -CN, eventuelt substitueret Ci-6alkyl, nitro, N (Ra) 2t -C (O) N (Ra) 2r -C02Ra eller -C(0)Ra.
3. Forbindelse ifølge krav 2 med formel IA1, IA2, IB1, IB2 eller IB3:
IA1
IA2
IB1
IB2
IB3 hvor r formel IA1 og IA2 R er H; R er halogen eller Ci_ 6alkyl; Z1 er CH, C-halogen eller C-eventuelt substitueret Ci_ 6alkyl; og Z2 er CH; og i formel IBl, IB2 og IB3: hver af R2a, R2b, R2c og R2d uafhængigt for hver forekomst er som defineret for R2.
4. Forbindelse med formel IA1 eller IA2 ifølge krav 3, hvor: R5 er F eller CH3, og hver af R2a, R2b og R2c uafhængigt for hver forekomst eventuelt er Ci_6alkyl, -0Ra, -OCF3, -SRa, -N(RC)2, halogen, -OCH2F,-OCF2H, -CF3, -CN, -S(0)2Ra, -C(0)Ra, -C02Ra, - C(0)N(Rc)2, - (C (Ra) 2) m-Rb eller - [N (Ra) C (0) ] nRa, fortrinsvis hvor den ene af følgende muligheder (a) til (e) gælder: (a) R2a, R2b og R2c hver for sig er Ci-6alkyl, -0Ra, -OCF3, halogen, -CF3 eller -CN; (b) R2a er CH3; R2b er halogen; og R2c er CH3. (c) R2a er CH3; R2b er CH3; og R2c er halogen. (d) R2a er CH3; R2b er CH3; og R2c er CH3. (e) R2b er H; og R5 er F eller CH3; og hver af R2a og R2g uafhængigt for hver forekomst eventuelt er H, Ci_6alkyl, -0Ra, -0CF3, -SRa, -N(Rc)2, halogen, -0CF2H, -0CH2F,-CF3, -CN, -S(0)2Ra, -C(0)Ra, -C02Ra, -C(0)N(Rc)2, -C(Ra)2-N(Rc)2 eller [N (Ra) C (0) ] nRa; og den ene af R2a og R2c ikke er H, fortrinsvis H, Ci_6alkyl, -0Ra, -0CF3, halogen, -CF3, -C (Ra) 2-N (Rc) 2 eller - CN, mere fortrinsvis hvor R2a er -CF3 eller -CH3; og R2c er halogen eller -CH3.
5. Forbindelse med formel IA1 eller IA1 ifølge krav 2, hvor: (a) R2a er H, -CH3, -CF3, -0Ra eller -0CF3; og R2c er -C (Ra) 2- N (Rc) 2; eller (b) R2c er H; og R5 er F eller CH3; og hvor hver af R2a og R2b fortrinsvis er H, Ci_6alkyl, -0Ra, -0CF2H, -0CF3, -0CH2F,-SRa, - N(Rc)2, halogen, -CF3, -CN, -S(0)2Ra, -C(0)Ra, -C02Ra, C(0)N(Rc)2, -C (Ra) 2-N (Rc) 2 eller - [N (Ra) C (0) ] nRa; og den ene af R2a og R2b fortrinsvis ikke er H.
6. Forbindelse med formel IA, IA1 eller IA2 ifølge krav 5, hvor mulighed (b) gælder, eller krav 2 eller 3, hvor hver af R2a og R2b er H, Ci_6alkyl, -0Ra, -0CF3, halogen, -N(RC)2, -CF3, - C (Ra) 2-N (Rc) 2 eller -CN, og hvor den ene af mulighederne (i), (ii) og (iii) gælder: (i) R2b er -CF3 eller -CH3; og R2a er halogen eller -CH3; (ii) R2a er H, -CH3, -CF3, -0Ra eller -0CF3; og R2b er -N (Rc) 2 eller -C (Ra) 2-N (Rc) 2; (iii) R2a er -N(RC)2 eller -C (Ra) 2-N (Rc) 2; og R2b er H, -CH3,-CF3, -0Ra eller -OCF3.
7. Forbindelse med formel ΙΑ, ΙΑ1 eller IA2 ifølge krav 5, hvor mulighed (b) gælder, eller krav 2, hvor R2a og R2b sammen med carbonatomerne, hvortil de er bundet, danner en 4-10-leddet, delvist eller helt mættet, mono- eller bicyklisk ring, der eventuelt indeholder et eller flere heteroatomer og eventuelt er substitueret med et eller flere Ra og/eller Rb; fortrinsvis en 5-leddet, delvist eller helt mættet, monocyklisk ring, der eventuelt indeholder et eller flere heteroatomer og eventuelt er substitueret med et eller flere Ra og/eller Rb; mere fortrinsvis en cyclopentan-, pyrrolidin-, imidazolidin-, 1,3-dioxolan-, oxazolidin- eller tetrahydrofuranring; eventuelt substitueret med et eller flere Ra og/eller Rb.
8. Forbindelse ifølge krav 1 eller forbindelse med formel IB1 eller IB2 ifølge krav 3, hvor X og Y hver for sig er NR1, fortrinsvis NH eller NCi_6alkyl, mere fortrinsvis NH eller NCH3, og eventuelt også hvor R5 er halogen eller Ci_6alkyl; Z1 er C-H, C-halogen eller C-eventuelt substitueret Ci-6alkyl; og Z2 er C, og fortrinsvis også hvor R2c og R2d i formel I eller R2a og R2d i formel IB1 og IB2 er H; og R5 er F eller CH3; og mere fortrinsvis også hvor hver af substituenterne R2a og R2b i formel I eller substituenterne R2a og R2c i formel IB1 og IB2 uafhængigt for hver forekomst er H, Ci-6alkyl, -ORa, -OCF3, SRa, -N(Rc)2, halogen, -OCF2H, -OCH2F, -CF3, -CN, -S (O) 2Ra, -C (O) Ra, -C02Ra, -C(0)N(Rc)2 eller - [N (Ra) C (O) ] nRa; og den ene af substituenterne ikke er H, hvor: (i) hver af substituenterne uafhængigt for hver forekomst fortrinsvis er H, -N(RC)2, halogen, -CF3, -CN, -S (O) 2Ra, C(0)Ra, -C02Ra eller -C(0)N(Rc)2, mere fortrinsvis (ii) hvor R2a i formel I er H, halogen eller cyano; og R2b i formel I er halogen, -CF3, -CN, -S(0)2Ra, -C(0)Ra, -C02Ra eller -C(0)N(Rc)2; endnu mere fortrinsvis (iii) hvor R2a i formel I er halogen, -CF3, -CN, -S (O) 2Ra, C(0)Ra, -C02Ra eller -C (O) N (Rc) 2; og R2b i formel I er H, halogen eller cyano, endnu mere fortrinsvis (iv) hvor forbindelsen har formel IA3
IA3 hvor Rb er OH, Ci_6alkyl, -C02Ci-6alkyl, -C (0) Ci_6alkyl eller -S (0) 2Ci_6alkyl; og fortrinsvis også hvor (v) R2b i formel IB1 og IB2 er H, halogen, -CF3, -CN eller -CH3; og R2c er -N(RC)2, -S(0)2Ra, -C(0)N(Rc)2 eller -C (Ra) 2-N (Rc) 2, eller (vi) R2b i formel IB2 er H, halogen, -CF3, -CN eller -CH3; og R2c er -N(Rc)2 eller -C (Ra) 2-N (Rc) 2.
9. Forbindelse ifølge krav 8, hvor betingelse (i) gælder, og R2a og R2b i formel I sammen med carbonatomerne, hvortil de er bundet, danner en 6, 7 eller 8-leddet, delvist eller helt mættet, monocyklisk ring, der eventuelt indeholder et eller flere heteroatomer og eventuelt er substitueret med et eller flere Ra og/eller Rb, hvilken ring fortrinsvis er cyclohexan, morpholin, piperidin, dioxan, oxathiazinan, cycloheptan, cyclohepten, azepan, tetrahydroazepin, diazepan, cyclooctan, cycloocten, azocan, hexahydroazocin, diazocan eller hexahydrodiazocin; eventuelt substitueret med et eller flere Ra og/eller Rb.
10. Forbindelse med formel IB1, IB2 eller IB3 ifølge krav 3, hvor X er 0, og Y er NR1; og hvor R5 eventuelt er halogen eller Ci_6alkyl; Z1 eventuelt er CH, C-halogen eller C-eventuelt substitueret Ci_6alkyl; og Z2 eventuelt er CH, og fortrinsvis også hvor R2a og R2d er H; og R5 er F eller CH3, og mere fortrinsvis også hvor (i) hver af R2b og R2c uafhængigt for hver forekomst er H, C3_ 6alkyl, -0Ra, -0CF3, -SRa, -N(RC)2, halogen, -0CF2H, -0CH2F,-CF3, -CN, -S (0) 2Ra, -C (0) Ra, -C02Ra, -C(0)N(Rc)2, -C (Ra) 2-N (Rc) 2 eller - [N (Ra) C (0) ] nRa; og den ene af R2b og R2c ikke er H, (ii) hver af R2b og R2c uafhængigt for hver forekomst er H, C2-ealkyl, -N(RC)2, halogen, -CF3, -CN, -S(0)2Ra, -C(0)Ra, -C02Ra, -C(0)N(Rc)2 eller -C (Ra) 2-N (Rc) 2, hvor (a) R2b fortrinsvis er H, halogen, -CF3, -CN eller -CH3; og R2c fortrinsvis er -N(RC)2, -S(0)2Ra, -C(0)N(Rc)2 eller -C (Ra) 2- N(Rc)2, eller hvor (b) R2b fortrinsvis er H, halogen, -CF3, -CN eller -CH3; og R2c fortrinsvis er -N (Rc) 2 eller -C (Ra) 2_N (Rc) 2; eller (iii) R2a og R2b sammen med carbonatomerne, hvortil de er bundet, danner en 4-10-leddet, delvist eller helt mættet, mono- eller bicyklisk ring, der eventuelt indeholder et eller flere heteroatomer og eventuelt er substitueret med et eller flere Ra og/eller Rb, hvilken ring fortrinsvis er en cyclopentan-, pyrrolidin-, imidazolidin-, 1,3-dioxolan-, oxazolidin-, tetrahydrofuran-, cyclohexan-, morpholin-, piperidin-, dioxan-, oxathiazinan-, piperazin-, cycloheptan-, cyclohepten-, azepan-, tetrahydroazepin-, diazepan-, cyclooctan-, cycloocten-, azocan-, hexahydroazocin-, diazocan-eller hexahydrodiazocinring; eventuelt substitueret med et eller flere Ra og/eller Rb.
11. Forbindelse ifølge krav 1, hvor ring A er indazol, benzoxazol, pyrazolopyridin eller isoxozolopyridin; X er 0; Y er NR1; R5 er halogen eller Ci_6alkyl; Z1 er CH, C-halogen eller C-eventuelt substitueret Ci_6alkyl; Z2 er CH; og hvert R2 uafhængigt for hver forekomst er H, Ci_6alkyl, -0Ra, -0CF3, SRa, -N(Rc)2, halogen, -0CF2H, -0CH2F, -CF3, -CN, -S (0) 2Ra, - C (0) Ra, -C02Ra, -C(0)N(Rc)2, -N (Ra)-S (0) 2Ra eller - [N (Ra) C (0) ] nRa; hvor forbindelsen fortrinsvis har formel II:
II hvor ring B er cyclopentan, pyrrolidin, imidazolidin, 1,3-dioxolan, oxazolidin, tetrahydrofuran, cyclohexan, morpholin, piperidin, dioxan, oxathiazinan, piperazin, cycloheptan, cyclohepten, azepan, tetrahydroazepin, diazepan, cyclooctan, cycloocten, azocan, hexahydroazocin, diazocan eller hexahydrodiazocin; Ra er Ci-6alkyl; og hvert Rb uafhængigt for hver forekomst er =0, -0Ra, halogenCi_3alkyloxy, -SRa, -N(RC)2, halogen, -CF3, -CN, -S(0)2Ra, -C(0)Ra, -C02Ra, -C(0)N(Rc)2 eller -C (Ra) 2_N (Rc) 2; mere fortrinsvis hvor R1 er H eller R50; R50 er -CH20P (0) (OR11) 2; og hvert R11 uafhængigt for hver forekomst er Ra eller en monovalent kationisk gruppe; eller to R11 sammen med atomerne, hvortil de er bundet, danner en 4-8-leddet cyklisk phosphatgruppe, eller to R11 sammen er en divalent kationisk gruppe; mest fortrinsvis hvor hvert R11 uafhængigt for hver forekomst er H, t-butyl, HOCH2CH2N (CH3) 3+, Na+, Li+ eller K+.
12. Forbindelse ifølge krav 5, hvor mulighed (a) gælder, og enten (i) en af R2a, R2b og R2c er:
eller
eventuelt substitueret med en eller flere af den samme eller forskellige Ra- og/eller Rb-grupper; eller (ii) en af R2a, R2b og R2c er -C (Ra) 2-N (Rc) 2, hvor -C (Ra) 2-N (Rc) 2 er:
eller
eventuelt substitueret med en eller flere af den samme eller forskellige Ra-og/eller Rb-grupper; fortrinsvis hvor R1 er H eller R50; R50 er -CH2OP (0) (OR11) 2; og hvert R11 uafhængigt for hver forekomst er Ra eller en monovalent kationisk gruppe; eller to R11 sammen med atomerne, hvortil de er bundet, danner en 4-8-leddet cyklisk phosphatgruppe, eller to R11 sammen er en divalent kationisk gruppe, mere fortrinsvis hvert R11 uafhængigt for hver forekomst er H, t-butyl, HOCH2CH2N (CH3) 3+, Na+, Li+ eller K+.
13. Forbindelse ifølge krav 1, hvor forbindelsen er: 1-1 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-(3-formylphenyl)-5- methylpyrimidin-2,4-diamin; 1-2 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-(3- aminocarbonylphenyl)-5-methylpyrimidin-2,4-diamin; 1-3 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2 - (4- aminocarbonylphenyl)-5-methylpyrimidin-2,4-diamin; 1-4 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-(4-formylphenyl)-5- methylpyrimidin-2,4-diamin; 1-5 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-(3-methyl-4-(1,5,7- trimethyl-3,7-diazabicyclo[3.3.1]nonan-3-yl)phenyl)-5-methylpyrimidin-2,4-diamin; 1-6 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-(3-fluor-4-(1,5,7- trimethyl-3,7-diazabicyclo[3.3.1]nonan-3-yl)phenyl)-5-methylpyrimidin-2,4-diamin; 1-7 N4-(3-n-propylbenzo[d]oxazol-2(3H)-on-5-yl)-N2-((3- methylsulfonyl) phenyl)-5-methylpyrimidin-2,4-diamin; 1-9 N4-(3-isopropylbenzo[d]oxazol-2(3H)-on-5-yl)-N2- ( (3- methylsulfonyl) phenyl)-5-methylpyrimidin-2,4-diamin; 1-16 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-(3- methylsulfonyl) phenyl)-5-methylpyrimidin-2,4-diamin; 1-17 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-(4- methylsulfonyl) phenyl)-5-methylpyrimidin-2,4-diamin; 1-20 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-(3- methylsulfonyl) phenyl)-5-fluorpyrimidin-2,4-diamin; 1-21 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-(4- methylsulfonyl) phenyl)-5-fluorpyrimidin-2,4-diamin; 1-22 N4-(benzimidazolin-2-on-5-yl)-N2- (3- methylsulfonyl) phenyl-5-methylpyrimidin-2,4-diamin; 1-23 N4-(benzimidazolin-2-on-5-yl)-N2-(4- methylsulfonyl) phenyl-5-fluorpyrimidin-2,4-diamin; 1-26 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-(3-cyanophenyl)-5- methylpyrimidin-2,4-diamin; 1-27 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-(4-cyanophenyl)-5- methylpyrimidin-2,4-diamin; 1-28 N4-(benzimidazolin-2-on-5-yl)-N2-(3-cyanophenyl)-5- methylpyrimidin-2,4-diamin; 1-29 N4-(benzimidazolin-2-on-5-yl)-N2-(4-cyanophenyl)-5- methylpyrimidin-2,4-diamin; 1-33 N4-(3-phosphorylmethylbenzo[d]oxazol-2(3H)-on-5-yl)-N2- ((3-methylsulfonyl) phenyl)-5-methylpyrimidin-2,4-diamin; 1-36 N4-(1,3-dimethylbenzimidazolin-2-on-5-yl)-N2-((3- methylsulfonyl) phenyl)-5-methylpyrimidin-2,4-diamin; 1-41 N4-(1,3-dimethylbenzimidazolin-2-on-5-yl)-N2- ( (3- methylsulfonyl) phenyl)-5-fluorpyrimidin-2,4-diamin; 1-44 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-(3-cyanophenyl)-5- fluorpyrimidin-2,4-diamin; 1-45 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-(4-cyanophenyl)-5- fluorpyrimidin-2,4-diamin; 1-46 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-((3- morpholinyl)phenyl)-5-methylpyrimidin-2,4-diamin; 1-47 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-((3- morpholinyl)phenyl)-5-fluorpyrimidin-2,4-diamin; 1-48 N4-(benzo[d]oxazol-2(3H)-on-6-yl)-N2-((3- morpholinyl)phenyl)-5-methylpyrimidin-2,4-diamin; 1-49 N4-(3-methylbenzo[d]oxazol-2(3H)-on-6-yl)-N2-( (3- morpholinyl)phenyl)-5-methylpyrimidin-2,4-diamin; 1-5 9 N2-((3-methylsulfonyl) phenyl)-N4-(3-methyl-2-oxo-2,3- dihydrobenzo[d]oxazol-6-yl)-5-fluorpyrimidin-2,4-diamin; 1-60 N2-(4-methylsulfonyl)phenyl)-N4-(3-methyl-2-oxo-2,3- dihydrobenzo[d]oxazol-6-yl)-5-fluorpyrimidin-2,4-diamin; 1-65 N2-((3-methylsulfonyl) phenyl)-N4-(3-methyl-2-oxo-2,3- dihydrobenzo[d]oxazol-6-yl)-5-methylpyrimidin-2,4-diamin; 1-66 N2-((4-methylsulfonyl)phenyl)-N4-(3-methyl-2-oxo-2,3- dihydrobenzo[d]oxazol-6-yl)-5-methylpyrimidin-2,4-diamin; 1-69 N2-((3-methylsulfonyl) phenyl)-N4-(3-methyl-2-oxo-2,3- dihydrobenzo[d]oxazol-5-yl)-5-methylpyrimidin-2,4-diamin; 1-70 N2-((4-methylsulfonyl)phenyl)-N4-(3-methyl-2-oxo-2,3- dihydrobenzo[d]oxazol-5-yl)-5-methylpyrimidin-2,4-diamin; 1-7 7 N2-((3-methylsulfonyl) phenyl)-N4-(3-methyl-2-oxo-2,3- dihydrobenzo[d]oxazol-5-yl)-5-fluorpyrimidin-2,4-diamin; 1-78 N2-((4-methylsulfonyl)phenyl)-N4-(3-methyl-2-oxo-2,3- dihydrobenzo[d]oxazol-5-yl)-5-fluorpyrimidin-2,4-diamin; 1-100 N2- ( (3-methylsulfonyl) phenyl)-N4-(2-oxo-2,3- dihydrobenzo[d]oxazol-6-yl)-5-methylpyrimidin-2,4-diamin; 1-101 N2-((4-methylsulfonyl)phenyl)-N4-(2-oxo-2,3- dihydrobenzo[d]oxazol-6-yl)-5-methylpyrimidin-2,4-diamin; 1-106 N4-(benzoxazolin-2-on-5-yl)-N2-(3- trifluormethoxyphenyl)-5-methylpyrimidin-2,4-diamintrifluoracetatsalt; 1-107 N4-(benzoxazolin-2-on-5-yl)-N2-(3- trifluormethoxyphenyl)-5-fluorpyrimidin-2,4-diamintrifluoracetatsalt; 1-108 N4-(benzoxazolin-2-on-5-yl)-N2-(4- trifluormethoxyphenyl) - 5-methylpyrimidin-2,4- diamintrifluoracetatsalt; 1-109 N4-(benzoxazolin-2-on-5-yl)-N2- (4- trifluormethoxyphenyl)-5-fluorpyrimidin-2,4-diamintrifluoracetatsalt; 1-110 N4-(benzoxazolin-2-on-5-yl)-N2-[3-trifluormethyl-4- (4- ethylpiperazin-l-yl)phenyl]-5-methylpyrimidin-2,4-diamin; 1-111 N4-(benzoxazolin-2-on-5-yl)-N2-[3-methyl-4-(4- methylpiperazin-l-yl)phenyl]-5-methylpyrimidin-2,4-diamin; 1-115 N4-(benzoxazolin-2-on-5-yl)-N2-(3,4,5-trimethoxyphenyl) - 5-fluorpyrimidin-2,4-diamin; 1-116 N2-(3-(difluormethoxy)-4-methoxyphenyl)-N4- (benzo[d]oxazol-2(3H)-on-5-yl)-5-methylpyrimidin-2,4-diamin; 1-117 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-(4- trifluormethylsulfonyl)phenyl-5-methylpyrimidin-2,4-diamin; 1-118 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-(3- trifluormethylsulfonyl)phenyl-5-methylpyrimidin-2,4-diamin; 1-119 N4 -(benzo[d]oxazol-2(3H)-on-5-yl)-N2-(3,4,5- trimethoxy)phenyl-5-methylpyrimidin-2,4-diamin; 1-120 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-( (4 - (1,4- diazabicyclo[3.2.2]nonan-4-yl)-3-methyl) phenyl)-5-methylpyrimidin-2,4-diamin; 1-121 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-(4-(8-methyl-8- azabicyclo[3.2.1]octan-3-ylamino) phenyl)-5-methylpyrimidin-2,4-diamin; 1-122 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-((4-(dihydro-lH- pyrido[1,2-a]pyrazin-2(6H,7H,8H,9H,9aH)-yl)-3-methyl) phenyl) -5-methylpyrimidin-2,4-diamin; 1-123 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2- (4-(8-methyl-2,8- diazabicyclo[3.2.1]octan-2-yl)phenyl)-5-methylpyrimidin-2,4-diamin; 1-124 N4-(benzo[d]oxazolin-2(3H)-on-5-yl)-5-methyl-N2-[3- (morpholin-4-yl)-4-trifluormethoxyphenyl]-2,4-pyrimidindiamin; 1-125 N4-(benzo[d]oxazolin-2(3H)-on-5-yl)-N2-[3- trifluormethyl-2-(4-methylpiperazin-l-yl)pyridin-5-yl]-5-methylpyrimidin-2,4-diamin; 1-126 4-[5-methyl-4-(2-oxo-2,3-dihydrobenzooxazol-5-ylamino)- pyrimidin-2-ylamino]-benzoesyre; 1-127 N-(2-diethylaminoethyl)-4-[5-methyl-4-(2-oxo-2,3- dihydrobenzooxazol-5-ylamino)-pyrimidin-2-ylamino]-benzamid; 1-128 5 —{2 —[4-(3-diethylaminopyrrolidin-l-carbonyl)- phenylamino]-5-methylpyrimidin-4-ylamino}-3H-benzooxazol-2-on; 1-129 5-[2-(4-acetylphenylamino)-5-methylpyrimidin-4-ylamino]- 3H-benzooxazol-2-on; 1-130 5-[2-(3-acetylphenylamino)-5-methylpyrimidin-4-ylamino]- 3H-benzooxazol-2-on; 1-131 2-methyl-5-[5-methyl-4-(2-oxo-2,3-dihydrobenzooxazol-5-ylamino)-pyrimidin-2-ylamino]-benzonitril; 1-132 N,N-dimethyl-4-[5-methyl-4-(2-oxo-2,3- dihydrobenzooxazol-5-ylamino)-pyrimidin-2-ylamino]-benzamid; 1-133 N-methyl-4-[5-methyl-4-(2-oxo-2,3-dihydrobenzooxazol-5-ylamino)-pyrimidin-2-ylamino]-benzamid; 1-134 N-cyclopropyl-4-[5-methyl-4-(2-oxo-2,3- dihydrobenzooxazol-5-ylamino)-pyrimidin-2-ylamino]-benzamidformatsalt; 1-135 4-[5-methyl-4-(2-oxo-2,3-dihydrobenzooxazol-5-ylamino)- pyrimidin-2-ylamino]-N-phenylbenzamid; 1-136 4-[5-methyl-4-(2-oxo-2,3-dihydrobenzooxazol-5-ylamino)- pyrimidin-2-ylamino]-2-pyrrolidin-1-ylbenzamid; 1-137 N-ethyl-4-[5-methyl-4-(2-oxo-2,3-dihydrobenzooxazol-5- ylamino)-pyrimidin-2-ylamino]-benzamid; 1-138 N-cyclobutyl-4-[5-methyl-4-(2-oxo-2,3- dihydrobenzooxazol-5-ylamino)-pyrimidin-2-ylamino]-benzamidmyresyresalt; 1-139 N-isopropyl-4-[5-methyl-4-(2-oxo-2,3-dihydrobenzooxazol- 5-ylamino)-pyrimidin-2-ylamino]-benzamid; 1-140 N-cyclopropyl-4-[5-methyl-4-(2-oxo-2,3- dihydrobenzooxazol-5-ylamino)-pyrimidin-2-ylamino]-benzamidformatsalt; 1-141 2-chlor-4-[5-methyl-4-(2-oxo-2,3-dihydrobenzooxazol-5- ylamino)-pyrimidin-2-ylamino]-benzamid; 1-142 N-cyclopropyl-4-[5-methyl-4-(2-oxo-2,3- dihydrobenzooxazol-5-ylamino)-pyrimidin-2-ylamino]-benzamidtrifluoreddikesyresalt; 1-143 N-cyclopropyl-4-[5-methyl-4-(2-oxo-2,3- dihydrobenzooxazol-5-ylamino)-pyrimidin-2-ylamino]-benzamid; 1-144 N-cyclobutyl-4-[5-methyl-4-(2-oxo-2,3- dihydrobenzooxazol-5-ylamino)-pyrimidin-2-ylamino]-benzamid; 1-145 4-[5-methyl-4-(2-oxo-3-propionyl-2,3-dihydrobenzooxazol- 5-ylamino)-pyrimidin-2-ylamino]-benzamid; 1-146 di-tert-butyl-(5-(2-(4-carbamoylphenylamino)-5- methylpyrimidin-4-ylamino)-2-oxobenzo[d]oxazol-3(2H)-yl)-methylphosphat; 1-147 (5-(2-(4-carbamoylphenylamino)-5-methylpyrimidin-4- ylamino)-2-oxobenzo[d]oxazol-3(2H) -yl) -methyldihydrogenphosphat; 1-148 natrium-(5-(2-(4-carbamoylphenylamino)-5- methylpyrimidin-4-ylamino)-2-oxobenzo[d]oxazol-3(2H)-yl)-methylphosphat; 1-150 (5-(2-(4-(cyclobutylcarbamoyl)phenylamino)-5- methylpyrimidin-4-ylamino)-2-oxobenzo[d]oxazol-3(2H)-yl)-methyldihydrogenphosphat; 1-151 natrium-(5-(2-(4-(cyclobutylcarbamoyl)phenylamino)-5- methylpyrimidin-4-ylamino)-2-oxobenzo[d]oxazol-3(2H)-yl)-methylphosphat; 1-152 di-tert-butyl- (5- (2- (4- (cyclobutylcarbamoyl)phenylamino)-5-methylpyrimidin-4-ylamino)-2-oxobenzo[d]oxazol-3(2H)-yl)-methylphosphat; 1-153 5-[2-(4-chlor-3-trifluormethylphenylamino)-5- methylpyrimidin-4-ylamino]-3H-benzooxazol-2-on; 1-154 5-[5-methyl-2-(4-methyl-3-trifluormethylphenylamino)- pyrimidin-4-ylamino]-3H-benzooxazol-2-on; 1-155 5-[5-methyl-2-(4-methylsulfanyl-3- trifluormethylphenylamino)-pyrimidin-4-ylamino]-3H-benzooxazol-2-on; 1-156 4-[5-methyl-4-(2-oxo-2,3-dihydrobenzooxazol-5-ylamino)- pyrimidin-2-ylamino]-2-(4-methylpiperidin-l-yl)-benzamid; 1-157 5-[2-(3-cyclopentansulfonylphenylamino)-5- methylpyrimidin-4-ylamino]-3H-benzooxazol-2-on; 1-158 5-[5-methyl-2-(3-trifluormethylphenylamino)-pyrimidin-4- ylamino]-3H-benzooxazol-2-on; 1-159 2-methyl-4-[5-methyl-4-(2-oxo-2,3-dihydrobenzooxazol-5- ylamino)-pyrimidin-2-ylamino]-benzoesyremethylester; 1-160 5-[5-methyl-2-(4-trifluormethylphenylamino)-pyrimidin-4- ylamino]-3H-benzooxazol-2-on; 1-161 5-[5-methyl-2-(4-trifluormethoxy-3- trifluormethylphenylamino)-pyrimidin-4-ylamino]-3H-benzooxazol-2-on; 1-162 5-[2-(3-fluor-5-trifluormethylphenylamino)-5- methylpyrimidin-4-ylamino]-3H-benzooxazol-2-ontrifluoracetatsalt; 1-163 5-[2-(4 — fluor-3-trifluormethoxyphenylamino)-5- methylpyrimidin-4-ylamino]-3H-benzooxazol-2-on; 1-164 5-[5-methyl-2-(4-methyl-3-trifluormethylphenylamino)- pyrimidin-4-ylamino]-3H-benzooxazol-2-ontrifluoreddikesyresalt; 1-165 5 —{2 —[4-(2-methoxyethoxy)-3-trifluormethylphenylamino]- 5-methylpyrimidin-4-ylamino}-3H-benzooxazol-2-on; 1-166 5-[2-(4-isopropyl-3-methylphenylamino)-5- methylpyrimidin-4-ylamino]-3H-benzooxazol-2-on; 1-167 5-[2-(3-chlor-4-trifluormethylphenylamino)-5- methylpyrimidin-4-ylamino]-3H-benzooxazol-2-on; 1-168 5-[2-(4-ethoxy-3-trifluormethylphenylamino)-5- methylpyrimidin-4-ylamino]-3H-benzooxazol-2-on; 1-169 5-[2-(3,5-bis-trifluormethylphenylamino)-5- methylpyrimidin-4-ylamino]-3H-benzooxazol-2-on; 1-170 2-methyl-4-[5-methyl-4-(2-oxo-2,3-dihydrobenzooxazol-5- ylamino)-pyrimidin-2-ylamino]-benzoesyre; 1-171 N-ethyl-2-methyl-4-[5-methyl-4-(2-oxo-2,3- dihydrobenzooxazol-5-ylamino)-pyrimidin-2-ylamino]-benzamid; 1-172 5-[2-(4-chlorphenylamino)-5-methylpyrimidin-4-ylamino]- 3H-benzooxazol-2-on; 1-173 5-[2-(3-chlorphenylamino)-5-methylpyrimidin-4-ylamino]- 3H-benzooxazol-2-on; 1-174 5-(5-methyl-2-phenylaminopyrimidin-4-ylamino)-3H- benzooxazol-2-on; 1-175 5-[2-(3-bromphenylamino)-5-methylpyrimidin-4-ylamino]- 3H-benzooxazol-2-on; 1-176 5-[2-(4-chlor-2,5-dimethylphenylamino)-5- methylpyrimidin-4-ylamino]-3H-benzooxazol-2-on; 1-177 N-{4 -[5-methyl-4-(2-oxo-2,3-dihydrobenzooxazol-5- ylamino)-pyrimidin-2-ylamino]-2-trifluormethylphenyl}-acetamid; 1-178 5-[2-(3,4-dimethylphenylamino)-5-methylpyrimidin-4- ylamino]-3H-benzooxazol-2-on; 1-179 5-[2-(4-cyclohexylmethoxy-3-trifluormethylphenylamino)- 5-methylpyrimidin-4-ylamino]-3H-benzooxazol-2-on; 1-180 5-[2-(4-chlor-3-trifluormethoxyphenylamino)-5- methylpyrimidin-4-ylamino]-3H-benzooxazol-2-on; 1-181 5-[2-(4-chlor-3-methoxyphenylamino)-5-methylpyrimidin-4- ylamino]-3H-benzooxazol-2-on; 1-182 5-[2-(4-chlor-3-ethoxyphenylamino)-5-methylpyrimidin-4- ylamino]-3H-benzooxazol-2-on; 1-183 5-[2-(4 — fluor-3-methoxyphenylamino)-5-methylpyrimidin-4- ylamino]-3H-benzooxazol-2-on; 1-184 5-[2-(3,5-dichlorphenylamino)-5-methylpyrimidin-4- ylamino]-3H-benzooxazol-2-on; 1-185 5-[2-(3-brom-5-chlorphenylamino)-5-methylpyrimidin-4- ylamino]-3H-benzooxazol-2-on; 1-186 5-[2-(3-chlor-5-fluorphenylamino)-5-methylpyrimidin-4- ylamino]-3H-benzooxazol-2-on; 1-187 3-chlor-5-[5-methyl-4-(2-oxo-2,3-dihydrobenzooxazol-5- ylamino)-pyrimidin-2-ylamino]-benzonitril; 1-188 5-[2-(4-brom-3-trifluormethylphenylamino)-5- methylpyrimidin-4-ylamino]-3H-benzooxazol-2-on; 1-189 5-[2-(3-brom-5-trifluormethylphenylamino)-5- methylpyrimidin-4-ylamino]-3H-benzooxazol-2-on; 1-190 N-cyclobutyl-2-methyl-4-[5-methyl-4-(2-oxo-2,3- dihydrobenzooxazol-5-ylamino)-pyrimidin-2-ylamino]-benzamid; 1-191 5 —{2 —[3-chlor-4-(2-morpholin-4-yl-ethoxy)-phenylamino]- 5-methylpyrimidin-4-ylamino}-3H-benzooxazol-2-on; 1-192 5-{5-methyl-2-[4-(2-morpholin-4-yl-ethoxy)-phenylamino]- pyrimidin-4-ylamino}-3H-benzooxazol-2-on; 1-193 5-[2-(2,4-difluor-5-methoxyphenylamino)-5- methylpyrimidin-4-ylamino]-3H-benzooxazol-2-on; 1-194 5-[2-(3-chlor-4-ethoxyphenylamino)-5-methylpyrimidin-4- ylamino]-3H-benzooxazol-2-on; 1-195 5-[2-(4-cyclobutylmethoxyphenylamino)-5-methylpyrimidin- 4-ylamino]-3H-benzooxazol-2-on; 1-196 5-[2-(4-isobutoxyphenylamino)-5-methylpyrimidin-4- ylamino]-3H-benzooxazol-2-on; 1-197 5-{5-methyl-2-[4-(3-methylbutoxy)-phenylamino]- pyrimidin-4-ylamino}-3H-benzooxazol-2-on; 1-198 5-[2-(3-chlor-4-trifluormethylphenylamino)-5- methylpyrimidin-4-ylamino]-3H-benzooxazol-2-ontrifluoreddikesyresalt; 1-199 5-[2-(3-fluor-5-methylphenylamino)-5-methylpyrimidin-4- ylamino]-3H-benzooxazol-2-on; 1-200 5-[2-(2,4-difluor-3-methoxyphenylamino)-5- methylpyrimidin-4-ylamino]-3H-benzooxazol-2-on; 1-201 5-(2-(4-(l-(azetidin-l-yl)ethyl)phenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-202 5-(2-(4-(1-(cyclopropylamino)ethyl)phenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-203 5-(5-methyl-2-(4-(1-(pyrrolidin-1- yl)ethyl)phenylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-204 5-(5-methyl-2-(4-(1- morpholinoethyl)phenylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-205 5-(2-(4-(1-(3-(diethylamino)pyrrolidin-1- yl)ethyl)phenylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-206 5-(2-(4-(1-(benzylamino)ethyl)phenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-207 5-(2-(4-(1-(isopropylamino)ethyl)phenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-208 5-(5-methyl-2-(3-(1- (propylamino)ethyl)phenylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-209 5-(2-(3-(1-(isopropylamino)ethyl)phenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-210 5-(2-(3-(1-(isopropylamino)ethyl)phenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-211 5-(2-(3-(l-(azetidin-l-yl)ethyl)phenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H) -on; 1-212 5-(5-methyl-2-(3-(1-(pyrrolidin-1- yl)ethyl)phenylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-213 5-(2-(3-(1-(benzylamino)ethyl)phenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-214 5-(2-(3-(1-(3-(diethylamino)pyrrolidin-1- yl)ethyl)phenylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2 (3H)-on; 1-215 5-(5-methyl-2-(3-(1-(piperidin-1- yl)ethyl)phenylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-216 5-(2-(3-(1-(diethylamino)ethyl)phenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-217 5-(5-methyl-2-(3-(1- morpholinoethyl)phenylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-218 N-cyclobutyl-4-(5-methyl-4-(2-oxo-2,3- dihydrobenzo[d]oxazol-5-ylamino)pyrimidin-2-ylamino)-2-(trifluormethyl)benzamid; 1-219 4-(5-methyl-4-(2-oxo-2,3-dihydrobenzo[d]oxazol-5- ylamino)pyrimidin-2-ylamino)-N-phenyl-2-(trifluormethyl)benzamid; 1-220 N-cyclopropyl-2-methoxy-4-(5-methyl-4-(2-oxo-2,3- dihydrobenzo[d]oxazol-5-ylamino)pyrimidin-2-ylamino)benzamid; 1-221 2-methoxy-4-(5-methyl-4-(2-oxo-2,3- dihydrobenzo[d]oxazol-5-ylamino)pyrimidin-2-ylamino)-N-phenylbenzamid; 1-222 4-(5-methyl-4-(2-oxo-2,3-dihydrobenzo[d]oxazol-5- ylamino)pyrimidin-2-ylamino)-2-(trifluormethyl)benzoesyre; 1-223 N-cyclopropyl-4-(5-methyl-4-(2-oxo-2,3- dihydrobenzo[d]oxazol-5-ylamino)pyrimidin-2-ylamino)-2-(trifluormethyl)benzamid; 1-224 5-(2-(3-isobutoxy-5-(trifluormethyl)phenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-225 5-(2-(3-(cyclopropylmethoxy)-5- (trifluormethyl) phenylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-226 5-(2-(3-cyclobutoxy-5-(trifluormethyl)phenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-227 5-(2-(3-(cyclobutylmethoxy)-5- (trifluormethyl)phenylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-228 5-(2-(3-deuteromethoxy-5-(trifluormethyl)phenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-229 5-(2-(3-acetyl-5-methoxyphenylamino)-5-methylpyrimidin- 4- ylamino)benzo[d]oxazol-2(3H)-on; 1-230 5-(2-(3-chlor-4-fluor-5-(trifluormethyl)phenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-231 5-(2-(3-(1-(isopropylamino)ethyl)-5-methoxyphenylamino)- 5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-232 5-(2-(3-methoxy-5-(1-(propylamino)ethyl)phenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-233 5-(2-(3-(1-(cyclopropylamino)ethyl)-5- methoxyphenylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-234 5-(2-(3-methoxy-5-(1-(pyrrolidin-1- yl)ethyl)phenylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-235 5-(2-(3-(1-(azetidin-l-yl)ethyl)-5-methoxyphenylamino)- 5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-236 5-(2-(3-methoxy-5-(1-(methylamino)ethyl)phenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-237 5-(2-(3-(difluormethyl)-5-methylphenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-238 5-(2-(3-(fluormethyl)-5-methylphenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-239 5-(5-methyl-2-(4-methyl-3- (methylsulfonyl)phenylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-240 5-(2-(3 — fluor-5-morpholinophenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-241 5-(2-(3-fluor-5-(4-methylpiperazin-l-yl)phenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-242 5-(2-(4-fluor-3-(methylsulfonyl)phenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H) -on; 1-244 7-methyl-5-(5-methyl-2- (3- (methylsulfonyl)phenylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-245 5-(2-(4-fluor-3-(methylsulfonyl)phenylamino)-5- methylpyrimidin-4-ylamino)-7-methylbenzo[d]oxazol-2(3H)-on; 1-246 5-(5-methyl-2-(3-(pyrrolidin-1- carbonyl)phenylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-247 5-(5-methyl-2-(4-(pyrrolidin-1- carbonyl)phenylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-249 7-fluor-5-(5-methyl-2-(3- (methylsulfonyl)phenylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-250 7-fluor-5-(2-(4-fluor-3-(methylsulfonyl)phenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-251 7-fluor-5-(2-(3-methoxy-5-(trifluormethyl)phenylamino)- 5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-252 3-methoxy-N,N-dimethyl-5-(5-methyl-4-(2-oxo-2,3- dihydrobenzo[d]oxazol-5-ylamino)pyrimidin-2-ylamino)benzamid; 1-253 5-(2-(3-methoxy-5-(pyrrolidin-l-carbonyl)phenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-254 5-(2-(3-methoxy-5-(morpholin-4-carbonyl)phenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-255 5-(2-(3-methoxy-5-(4-methylpiperazin-l- carbonyl)phenylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-256 5-(5-methyl-2-(3-(morpholin-4- carbonyl)phenylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-257 5-(5-methyl-2-(4-(morpholin-4- carbonyl)phenylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-258 5-(2-(4-methoxy-3-methylphenylamino)-5-methylpyrimidin- 4-ylamino)benzo[d]oxazol-2(3H)-on; 1-259 5-(2-(3-methoxy-5-methylphenylamino)-5-methylpyrimidin- 4-ylamino)benzo[d]oxazol-2(3H)-on; 1-260 2-methoxy-N,N-dimethyl-5-(5-methyl-4-(2-oxo-2,3- dihydrobenzo[d]oxazol-5-ylamino)pyrimidin-2-ylamino)benzamid; 1-261 5-(2-(4-methoxy-3-(pyrrolidin-l-carbonyl)phenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2 (3H)-on; 1-262 5-(2-(4-methoxy-3-(morpholin-4-carbonyl)phenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H) -on; 1-263 5-(2-(4-methoxy-3-(4-methylpiperazin-l- carbonyl)phenylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-264 5-(2-(3-methyl-4-trideuteromethoxyphenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-265 5-(2-(3-chlor-4-methoxy-5-methylphenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-266 5-(2-(3-methyl-5-trideuteromethoxyphenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-267 2-methoxy-N,N-dimethyl-4-(5-methyl-4-(2-oxo-2,3- dihydrobenzo[d]oxazol-5-ylamino)pyrimidin-2-ylamino)benzamid; 1-268 5-(2-(3-methoxy-4-(pyrrolidin-l-carbonyl)phenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-269 5-(2-(3-methoxy-4-(morpholin-4-carbonyl)phenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-270 5-(2-(3-methoxy-4-(4-methylpiperazin-l- carbonyl)phenylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-271 5-(2-(3-(difluormethyl)-4-methoxyphenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-272 5-(2-(4-methoxyphenylamino)-5-methylpyrimidin-4- ylamino)benzo[d]oxazol-2(3H)-on; 1-273 5-(2-(3-(difluormethyl)-5-methoxyphenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-274 5-(2-(3-(fluormethyl)-5-methoxyphenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-275 N2-[4-(4,4-difluorpiperidinyl)-3-fluor]phenyl-5-methyl- N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-276 N2-[4-(4,4-difluorpiperidinyl)-3-trifluormethyl]phenyl- 5-methyl-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-277 N2-[3-chlor-4-(4,4-difluorpiperidinyl)]phenyl-5-methyl- N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-278 N2-[3-chlor-4-(4-ethylpiperazino)]phenyl-5-methyl-N4-(2- oxo-2,3-dihydro-l, 3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-279 N2-[4-(4,4-difluorpiperidinyl)]phenyl-5-methyl-N4-(2- oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-280 N2-(3,5-dimethoxy)phenyl-5-methyl-N4-(2-oxo-2,3-dihydro- 1,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-281 N2-[3-fluor-4-(4-methylpiperazino)]phenyl-5-methyl-N4- (2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-282 N2-[3,5-difluor-4-(4-methylpiperazino)]phenyl-5-methyl- N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-283 N2-[4-chlor-3-(4-ethylpiperazino)]phenyl-5-methyl-N4-(2- oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-284 N2-[4-chlor-3-(3,4,5-trimethylpiperazino)]phenyl-5- methyl-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-285 5-methyl-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-N2-[3-(4-propylpiperazino)-4-trifluormethyl]phenyl-2,4-pyrimidindiamin; 1-286 5-methyl-N2-[3-(l,3-oxazol-5-yl)]phenyl-N4-(2-oxo-2,3- dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-287 N2-(3-brom)phenyl-5-methyl-N4-(2-oxo-2,3-dihydro-l,3- benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-288 N2-(4-brom)phenyl-5-methyl-N4-(2-oxo-2,3-dihydro-l,3- benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-289 5-methyl-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-N2-[3-(pyridin-4-yl)]phenyl-2,4-pyrimidindiamin; 1-290 5-methyl-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-N2-[3-(pyridin-3-yl)]phenyl-2,4-pyrimidindiamin; 1-291 5-methyl-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-N2-[4-(pyridin-3-yl)]phenyl-2,4-pyrimidindiamin; 1-292 N2-[4-methoxy-3-(2-methoxyethoxy)]phenyl-5-methyl-N4- (2- oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-293 N2-[3-(cyclopropylaminocarbonylmethoxy)-4- methoxy]phenyl-5-methyl-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-294 N2-(3-cyano-4-fluor)phenyl-5-methyl-N4-(2-oxo-2,3- dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-295 N2-[3-cyano-4-(lH-pyrrol-l-yl)]phenyl-5-methyl-N4-(2- oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-296 N2-(3-methoxy-5-trifluormethyl)phenyl-5-methyl-N4- (2- oxo-2,3-dihydro-l, 3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-297 N2-(4-methoxy-3-trifluormethyl)phenyl-5-methyl-N4-(2- oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-298 N2-{4-methoxy-3-[(pyridin-4-yl)methoxy]}phenyl-5-methyl- N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-299 N2-{4-methoxy-3-[(pyridin-3-yl)methoxy]}phenyl-5-methyl- N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-300 N2-{4-methoxy-3-[2-(dimethylamino)ethoxy]}phenyl-5- methyl-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-301 N2-[3,5-bis(trifluormethyl)]phenyl-5-methyl-N4-(2-oxo- 2.3- dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-302 N2-(3,5-dimethyl)phenyl-5-methyl-N4-(2-oxo-2,3-dihydro- 1.3- benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-303 N2-(4-cyano-3-trifluormethyl)phenyl-5-methyl-N4-(2-oxo- 2.3- dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-304 N2-[3-(1-hydroxy-2,2,2-trifluorethyl)]phenyl-5-methyl- N4- (2-oxo-2,3-dihydrol,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-305 N2-(3-methoxycarbonylmethoxy)phenyl-5-methyl-N4- (2-oxo- 2.3- dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-306 5-methyl-N2-(3-methylaminocarbonylmethoxy)phenyl-N4- (2-oxo-2,3-dihydro-l, 3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-307 N2-(4-aminocarbonylmethoxy)phenyl-5-methyl-N4-(2-oxo- 2.3- dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-308 5-methyl-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-N2-(4-phenylcarbonylamino)phenyl-2,4-pyrimidindiamin; 1-309 N2-[4-(N-acetyl-N-methyl) amino]phenyl-5-methyl-N4-(2- oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-310 N2-[3-cyano-4-(pyrrolidin-l-yl)]phenyl-5-methyl-N4-(2- oxo-2,3-dihydro-l, 3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-311 N2-(4-difluormethoxy)phenyl-5-methyl-N4- (2-oxo-2,3- dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-312 N2-(3-difluormethoxy)phenyl-5-methyl-N4-(2-oxo-2,3- dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-313 N2-(4-difluormethoxy-3-ethoxy)phenyl-5-methyl-N4-(2-oxo- 2.3- dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-314 N2-(3-chlor-4-difluormethoxy)phenyl-5-methyl-N4-(2-oxo- 2.3- dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-315 N2-[3-(cyclopropylaminocarbonylmethoxy)]phenyl-5-methyl- N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-316 N2-[3-aminocarbonyl-4-(4-methylpiperazino)]phenyl-5- methyl-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-317 N2-[4-(isopropoxycarbonylmethoxy)]phenyl-5-methyl-N4-(2- oxo-2,3-dihydro-l, 3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-318 N2-[4-(ethylaminocarbonylamino)]phenyl-5-methyl-N4-(2- oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-319 N2-[3-(aminocarbonylmethoxy)]phenyl-5-methyl-N4-(2-oxo- 2.3- dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-320 5-methyl-N2-[3-(morpholinocarbonylmethoxy)]phenyl-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-321 5-methyl-N2-[3-(4-methylpiperazin-l-yl)carbonyl]phenyl- N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-322 5-methyl-N2-[4-(4-methylpiperazin-l-yl)carbonyl]phenyl- N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-323 5-methyl-N2-[3-methylaminocarbonyl-4-(4- methylpiperazino)]phenyl-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-324 N2-[4-(1-aminocarbonyl-1-methyl)ethoxy]phenyl-5-methyl- N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-325 5-methyl-N2-(2-methyl-3- methylaminocarbonylmethoxy)phenyl-N4-(2-oxo-2,3-dihydro-l, 3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-326 N2-(3-dimethylaminocarbonylmethoxy)phenyl-5-methyl-N4- (2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-327 N2-(3-cyano-4-morpholino)phenyl-5-methyl-N4-(2-oxo-2,3- dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-328 N2-(3-methoxy-2-methyl)phenyl-5-methyl-N4-(2-oxo-2,3- dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-329 N2-[3-chlor-4-(pyridin-4-yl)]phenyl-5-methyl-N4-(2-oxo- 2.3- dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-330 5-methyl-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-Niti- (pyridin-4-yl)-3-trifluormethyl]phenyl-2,4-pyrimidindiamin; 1-331 N2-[3-hydroxymethyl-4-(4-methylpiperazino)]phenyl-5- methyl-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-332 5-methyl-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-N2-(4-piperazino)phenyl-2,4-pyrimidindiamin; 1-333 N2-[4-(4-ethylaminocarbonyl)piperazino]phenyl-5-methyl- N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-334 N2-[4-(1-cyano-l-methyl)ethoxy]phenyl-5-methyl-N4- (2- oxo-2,3-dihydro-l, 3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-335 N2-[3-(1-aminocarbonyl-1-methyl)ethoxy]phenyl-5-methyl- N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-336 N2-(3-methoxy-4-methoxycarbonyl)phenyl-5-methyl-N4-(2- oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-337 N2-(3-methoxy)phenyl-5-methyl-N4-(2-oxo-2,3-dihydro-l,3- benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-338 5-methyl-N2-(4-morpholino)phenyl-N4-(2-oxo-2,3-dihydro- 1.3- benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-339 N2-(3-cyano-4-thiomorpholino)phenyl-5-methyl-N4-(2-oxo- 2.3- dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-340 N2-[3-methoxy-4-(4-methylpiperazino)]phenyl-5-methyl-N4- (2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-341 N2-[3-cyano-4-(4-methylpiperazino)]phenyl-5-methyl-N4- (2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-342 N2-[3-(1-cyano-l-methyl)ethoxy]phenyl-5-methyl-N4-(2- oxo-2,3-dihydro-l, 3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-343 N2-[4-(4-acetyl)piperazino]phenyl-5-methyl-N4-(2-oxo- 2.3- dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-344 N2-[4-(4-ethoxycarbonyl)piperazino]phenyl-5-methyl-N4- (2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-345 N2-[3-(4-acetyl)piperazino]phenyl-5-methyl-N4-(2-oxo- 2.3- dihydro-l, 3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-346 N2-[3-(4-ethoxycarbonyl)piperazino]phenyl-5-methyl-N4- (2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-347 N2-(4-difluormethoxy-3-fluor)phenyl-5-methyl-N4-(2-oxo- 2.3- dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-348 N2-(3,5-dichlor-4-difluormethoxy)phenyl-5-methyl-N4-(2- oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-349 N2-(4-fluor-3-methoxy)phenyl-5-methyl-N4-(2-oxo-2,3- dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-350 N2-(3-fluor-4-methoxy)phenyl-5-methyl-N4-(2-oxo-2,3- dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-351 N2-(3-methoxy-4-methyl)phenyl-5-methyl-N4-(2-oxo-2,3- dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-352 N2-(3-fluor-5-methoxy)phenyl-5-methyl-N4-(2-oxo-2,3- dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-353 N2-(3-difluormethoxy-5-trifluormethyl)phenyl-5-methyl- N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-354 N2-(3-methoxy-4-trifluormethyl)phenyl-5-methyl-N4-(2- oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-355 N2-(3,5-di-tert-butyl)phenyl-5-methyl-N4-(2-oxo-2,3- dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-356 N4-{3-[bis(1,1-dimethylethoxy)]phosphinyloxymethyl-2- oxo-2,3-dihydro-l,3-benzoxazol-5-yl}-N2-(3-methoxy-5-trifluormethyl) phenyl-5-methyl-2,4-pyrimidindiamin; 1-357 N2-(3-methoxy-5-trifluormethyl)phenyl-5-methyl-N4-[3- (phosphonooxy)methyl-2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl]- 2.4- pyrimidindiamin; 1-358 N2-(3-methoxy-5-trifluormethyl)phenyl-5-methyl-N4-[3- (phosphonooxy)methyl-2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl]- 2.4- pyrimidindiamin-bis-natriumsalt; 1-359 N2-(3,5-difluor)phenyl-5-methyl-N4-(2-oxo-2,3-dihydro- 1.3- benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-360 N2-(3-fluor-5-trifluormethyl)phenyl-5-methyl-N4-(2-oxo- 2.3- dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-361 N2-(4-fluor-3-trifluormethyl)phenyl-5-methyl-N4-(2-oxo- 2.3- dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-362 N2-(4-fluor-3-methyl)phenyl-5-methyl-N4-(2-oxo-2,3- dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-363 N2-(3-fluor-4-methyl)phenyl-5-methyl-N4-(2-oxo-2,3- dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-364 N2-(3-chlor-4-methyl)phenyl-5-methyl-N4-(2-oxo-2,3- dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-366 N2-(3-chlor-4-trifluormethoxy)phenyl-5-methyl-N4-(2-oxo- 2.3- dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-367 N2-(4-trifluormethylthio)phenyl-5-methyl-N4-(2-oxo-2,3- dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-368 N2-(3-fluor)phenyl-5-methyl-N4-(2-oxo-2,3-dihydro-l,3- benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-369 N2-(3,5-dimethyl-4-methoxy)phenyl-5-methyl-N4-(2-oxo- 2.3- dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-370 N2-(3-carboxamid-5-trifluormethyl)phenyl-5-methyl-N4-(2- oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-371 N2-(3,5-diisopropyl-4-methoxy)phenyl-5-methyl-N4-(2-oxo- 2.3- dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-372 N2-(3-isopropoxy-5-trifluormethyl)phenyl-5-methyl-N4-(2- oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-373 N2-(3-cyano-4-methoxy)phenyl-5-methyl-N4-(2-oxo-2,3- dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-374 N2-(3,5-dimethyl-4-fluor)phenyl-5-methyl-N4-(2-oxo-2,3- dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-375 N2-(4-fluor-3-trifluormethoxy)phenyl-5-methyl-N4-(2-oxo- 2.3- dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-376 N2-(3 — fluor-4-trifluormethoxy)phenyl-5-methyl-N4-(2-oxo- 2.3- dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-377 N2-(4-chlor-3-trifluormethoxy)phenyl-5-methyl-N4-(2-oxo- 2.3- dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-378 N2-(3-chlor-5-trifluormethoxy)phenyl-5-methyl-N4-(2-oxo- 2.3- dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-379 5-methyl-N2-(3-methyl-5-trifluormethoxy)phenyl-N4- (2- oxo-2,3-dihydro-l, 3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-380 N2-(4-cyano-3-methoxy)phenyl-5-methyl-N4-(2-oxo-2,3- dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-381 N2-(3,5-difluor-4-methoxy)phenyl-5-methyl-N4-(2-oxo-2,3- dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-382 5-methyl-N2-(4-morpholinomethyl)phenyl-N4-(2-oxo-2,3- dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-383 N2-(4-chlor-3-cyano-5-ethyl)phenyl-5-methyl-N4-(2-oxo- 2.3- dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-384 N2-[3-(2-methoxy)ethoxy-5-trifluormethyl]phenyl-5- methyl-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-385 N2-(4-difluormethoxy-3,5-dimethyl)phenyl-5-methyl-N4-(2- oxo-2,3-dihydro-l, 3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-386 N2-[3-(1-aminocarbonyl-1-methyl)ethoxy-4-fluor]phenyl-5- methyl-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-387 N2-(4-difluormethoxy-3-methyl)phenyl-5-methyl-N4-(2-oxo- 2.3- dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-388 N2-(3,5-difluor-4-difluormethoxy)phenyl-5-methyl-N4- (2- oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-389 N2-[4-(1-aminocarbonyl-l-methyl)ethoxy-3,5- dimethyl]phenyl-5-methyl-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-390 N2-(3-difluormethoxy-4-methyl)phenyl-5-methyl-N4-(2-oxo- 2.3- dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-391 N2-[4-(1-aminocarbonyl-l-methyl)ethoxy-3-methyl]phenyl- 5-methyl-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-392 N2-[3-(1-aminocarbonyl-1-methyl)ethoxy-4-methyl]phenyl- 5-methyl-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-393 N2-(3-methoxy-5-trifluormethyl)phenyl-5-methyl-N4-(2- oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiaminbesylatsalt; 1-394 N2-(4-chlor-3,5-dimethyl)phenyl-5-methyl-N4-(2-oxo-2,3- dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-395 N2-[4-(1-aminocarbonyl-l-methyl)ethoxy-3,5- difluor]phenyl-5-methyl-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-396 N2-[3-(l-methoxy-2,2,2-trifluorethyl)]phenyl-5-methyl- N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-397 N2-[3-(1-cyano-l-methyl)ethoxy-4-methyl]phenyl-5-methyl- N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-398 N2-(3,4-difluor)phenyl-5-methyl-N4-(2-oxo-2,3-dihydro- 1.3- benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-399 N2-(3-chlor-4-fluor)phenyl-5-methyl-N4-(2-oxo-2,3- dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-400 N2-(4-chlor-3-fluor)phenyl-5-methyl-N4-(2-oxo-2,3- dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-401 N2-(3-difluormethoxy-5-fluor)phenyl-5-methyl-N4-(2-oxo- 2.3- dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-402 N2-[3-(1-aminocarbonyl-l-methyl)ethoxy-5-fluor]phenyl-5- methyl-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-403 5-(5-methyl-2-m-tolylaminopyrimidin-4-ylamino)-3H- benzooxazol-2-on; 1-404 5 —{2 —[4-(3-dimethylaminopropoxy)-3- trifluormethylphenylamino]-5-methylpyrimidin-4-ylamino}-3H-benzooxazol-2-on; 1-405 N4-{3-[bis(1,1-dimethylethoxy)]phosphinyloxymethyl-2- oxo-2,3-dihydro-l,3-benzoxazol-5-yl}-N2- (3,4,5-trimethyl)phenyl-5-methyl-2,4-pyrimidindiamin; 1-406 5-methyl-N4-[3-(phosphonooxy)methyl-2-oxo-2,3-dihydro- 1.3- benzoxazol-5-yl]-N2-(3,4,5-trimethyl)phenyl-2,4-pyrimidindiamin; 1-407 5-methyl-N4-[3-(phosphonooxy)methyl-2-oxo-2,3-dihydro- 1.3- benzoxazol-5-yl]-N2-(3,4,5-trimethyl)phenyl-2,4-pyrimidindiamin-bis-natriumsalt; 1-408 5-methyl-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-N2-(3,4,5-trifluor)phenyl-2,4-pyrimidindiamin; 1-409 N2-(3-methoxy-5-trifluormethyl)phenyl-5-methyl-N4-(2- oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamintosylatsalt; 1-410 N2-(3-methoxy-5-trifluormethyl)phenyl-5-methyl-N4-(2- oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiaminmesylatsalt; 1-411 N2-(3-methoxy-5-trifluormethyl)phenyl-5-methyl-N4-(2- oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiaminsulfatsalt; 1-412 N2-(3-methoxy-5-trifluormethyl)phenyl-5-methyl-N4- (2- oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiaminhydrogenchloridsalt; 1-413 N2-(3-methoxy-5-trifluormethyl)phenyl-5-methyl-N4- (2- oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiaminnatriumsalt; 1-414 N2-(3-methoxy-5-trifluormethyl)phenyl-5-methyl-N4-(2- oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamincholinsalt; 1-415 N2-(3,5-difluor-4-trifluormethyl)phenyl-5-methyl-N4-(2- oxo-2,3-dihydro-l, 3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-416 N2-[3-(1-cyano-l-methyl)ethoxy-5-fluor]phenyl-5-methyl- N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-417 N2-[3-(1-cyano-l-methyl)ethoxy-4-fluor]phenyl-5-methyl- N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-418 N2-(4-chlor-3-difluormethoxy)phenyl-5-methyl-N4-(2-oxo- 2.3- dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-419 5-(2-(4-isopropylphenylamino)-5-methylpyrimidin-4- ylamino)benzo[d]oxazol-2(3H)-on; 1-420 5-(2-(4-tert-butylphenylamino)-5-methylpyrimidin-4- ylamino)benzo[d]oxazol-2(3H)-on; 1-421 5-(2-(p-toluidino)-5-methylpyrimidin-4- ylamino)benzo[d]oxazol-2(3H)-on; 1-422 5-(2-(3-(isopropoxymethyl)-4-methoxyphenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-423 5-(2-(3-(1-hydroxyethyl)-5-methoxyphenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-424 5-[2-(3-chlor-4-hydroxyphenylamino)-5-methylpyrimidin-4- ylamino]-3H-benzooxazol-2-on; 1-425 5-[2-(4-hydroxyphenylamino)-5-methylpyrimidin-4- ylamino]-3H-benzooxazol-2-on; 1-426 5 —{2 —[4-(2-dimethylaminoethoxy)-phenylamino]-5- methylpyrimidin-4-ylamino}-3H-benzooxazol-2-on; 1-427 5-(2-(3-methoxy-5-(trifluormethyl)phenylamino)-5- methylpyrimidin-4-ylamino)-7-methylbenzo[d]oxazol-2(3H) -on; 1-428 5-(2-(3-methoxy-5-methylphenylamino)-5-methylpyrimidin- 4-ylamino)-7-methylbenzo[d]oxazol-2(3H)-on; 1-429 5-(2-(4-methoxy-3-methylphenylamino)-5-methylpyrimidin- 4-ylamino)-7-methylbenzo[d]oxazol-2(3H)-on; 1-430 7-fluor-5-(2-(3-methoxy-5-methylphenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H) -on; 1-431 7-fluor-5-(2-(4-methoxy-3-methylphenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-432 5-(2-(4-fluor-3-methoxy-5-methylphenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-433 5-(2-(4-(difluormethoxy)-3-(fluormethyl)phenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-onformatsalt; 1-434 N2-(4-cyano-3-difluormethoxy)phenyl-5-methyl-N4-(2-oxo- 2.3- dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-435 N2-(3-difluormethoxy-4-fluor)phenyl-5-methyl-N4-(2-oxo- 2.3- dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-436 5-methyl-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-N2- (3,4,5-trimethyl)phenyl-2,4-pyrimidindiaminnatriumsalt; 1-437 N2-(3,5-dimethyl-4-fluor)phenyl-5-methyl-N4-(2-oxo-2,3- dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidindiaminnatriumsalt; 1-438 5-(2-(3-(difluormethyl)-4-methylphenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-439 5-(2-(3-(fluormethyl)-4-methylphenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-440 5-(2-(3-(difluormethyl)-5-methoxyphenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-onformatsalt; 1-441 5- (2- (4-d3-methoxy-3-(trifluormethyl)phenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-442 5-(2-(4-(difluormethoxy)-3-(difluormethyl)phenylamino)- 5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-onformatsalt; 1-443 5-(5-methyl-2-(4-methyl-3-(pyridin-4- yl)phenylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H) -on; 1-444 5-(5-methyl-2-(4-methyl-3-(pyridin-3- yl)phenylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-445 5-(2-(3-acetyl-5-(trifluormethyl)phenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-446 5-(2-(3-(1-hydroxyethyl)-5-(trifluormethyl)phenylamino)- 5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H) -on; 1-447 5- [2- (4-d3-methoxyphenylamino)-5-methylpyrimidin-4- ylamino]-3H-benzooxazol-2-on; 1-448 5-[2- (3-chlor-4-d3-methoxyphenylamino)-5-methylpyrimidin-4-ylamino]-3H-benzooxazol-2-on; 1-449 5 —{2 —[4-(2-diethylaminoethoxy)-phenylamino]-5- methylpyrimidin-4-ylamino}-3H-benzooxazol-2-on; 1-450 N4-{3-[bis(1,1-dimethylethoxy)]phosphinyloxymethyl-2- oxo-2,3-dihydro-l,3-benzoxazol-5-yl}-N2-(3,5-dimethyl-4-fluor)phenyl-5-methyl-2,4-pyrimidindiamin; 1-451 N2-(3,5-dimethyl-4-fluor)phenyl-5-methyl-N4-[3- (phosphonooxy)methyl-2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl]- 2,4-pyrimidindiamin-bis-natriumsalt; 1-452 5-(2-(3,4-dimethoxy-5-methylphenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-453 5-(2-(3,4-dimethoxy-5-methylphenylamino)-5- methylpyrimidin-4-ylamino)-7-methylbenzo[d]oxazol-2(3H)-on; 1-454 5-(2-(3,4-dimethoxy-5-methylphenylamino)-5- methylpyrimidin-4-ylamino)-7-fluorbenzo[d]oxazol-2(3H) -on; 1-455 5 —{2 —[3-chlor-4-(2-diethylaminoethoxy)-phenylamino]-5- methylpyrimidin-4-ylamino}-3H-benzooxazol-2-on; 1-456 5-[2-(2,4-difluorphenylamino)-5-methylpyrimidin-4- ylamino]-3H-benzooxazol-2-on; 1-457 5-(5-methyl-2-(3-(1-(methylamino)ethyl)-5- (trifluormethyl)phenylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-458 5-(2-(3-chlor-4,5-dimethoxyphenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-459 5-(2-(3,5-dimethyl-4-(2-morpholinoethoxy)phenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-460 5-(5-methyl-2-(3-(1-(methylamino)butyl)-5- (trifluormethyl)phenylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-461 5-(2-(3-(1-(cyclopropylamino)ethyl)-5- (trifluormethyl)phenylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-462 5-(2-(3-(1-(ethylamino)ethyl)-5- (trifluormethyl)phenylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-463 5-(5-methyl-2-(3-(1-(pyrrolidin-l-yl)ethyl)-5- (trifluormethyl)phenylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-464 5-(2-(3-(l-(azetidin-l-yl)ethyl)-5- (trifluormethyl)phenylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-465 5-(2-(3-(1-(cyclobutylamino)ethyl)-5- (trifluormethyl)phenylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-466 5-[2-(2,5-difluorphenylamino)-5-methylpyrimidin-4- ylamino]-3H-benzooxazol-2-on; 1-467 5-[2-(2,3-difluorphenylamino)-5-methylpyrimidin-4- ylamino]-3H-benzooxazol-2-on; 1-468 5-[2-(2-Fluorphenylamino)-5-methylpyrimidin-4-ylamino]- 3H-benzooxazol-2-on; 1-469 N-Cyclobutyl-3-[5-methyl-4- (2-oxo-2,3- dihydrobenzooxazol-5-ylamino)-pyrimidin-2-ylamino]-5-trifluormethylbenzamid; 1-470 5-[2-(4-Fluorphenylamino)-5-methylpyrimidin-4-ylamino]- 3H-benzooxazol-2-on; 1-471 5-(2-(4-fluor-3-(pyridin-4-yl)phenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-472 5-(2-(4-fluor-3-(pyridin-3-yl)phenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-473 5-(2-(3-(1-(isopropylamino)ethyl)-5- (trifluormethyl)phenylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-474 5-(2-(3,5-dimethylphenylamino)-5-methylpyrimidin-4- ylamino)-7-methylbenzo[d]oxazol-2(3H)-on; 1-475 7-methyl-5-(5-methyl-2-(3,4,5- trimethylphenylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-476 5-(2-(4-fluor-3,5-dimethylphenylamino)-5- methylpyrimidin-4-ylamino)-7-methylbenzo[d]oxazol-2(3H)-on; 1-477 5-[5-Methyl-2-(2,3,4,5-tetrafluorphenylamino)-pyrimidin- 4-ylamino]-3H-benzooxazol-2-on; 1-478 N2-(3-cyano-5-difluormethoxy)phenyl-5-methyl-N4-(2-oxo- 2.3- dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-479 5-methyl-N2-(3-methyl-5-trifluormethyl)phenyl-N4-(2-oxo- 2.3- dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-480 5-[5-Methyl-2-(2,3,5-trifluorphenylamino)-pyrimidin-4- ylamino]-3H-benzooxazol-2-on; 1-481 5-[5-Methyl-2-(2,4,5-trifluorphenylamino)-pyrimidin-4- ylamino]-3H-benzooxazol-2-on; 1-482 5-(5-methyl-2-(3-methyl-4-(pyridin-4- yl)phenylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-onformatsalt; 1-483 5-(5-methyl-2-(3-methyl-4-(pyridin-3- yl)phenylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-onformatsalt; 1-484 5-(2-(3-fluor-4-(pyridin-4-yl)phenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-485 N2-(3,4-dimethoxy-5-trifluormethyl)phenyl-5-methyl-N4- (2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-486 5-(2-(4-methoxy-3-(pyridin-4-yl)phenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-onformatsalt; 1-487 5-(2-(4-methoxy-3-(pyridin-3-yl)phenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-onformatsalt; 1-488 5-(2-(3,5-dimethylphenylamino)-5-methylpyrimidin-4- ylamino)-7-fluorbenzo[d]oxazol-2(3H)-on; 1-489 7-fluor-5-(5-methyl-2- (3,4,5- trimethylphenylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-490 7-fluor-5-(2-(4-fluor-3,5-dimethylphenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-491 5-(2-(4 — fluor-3-methoxy-5-methylphenylamino)-5- methylpyrimidin-4-ylamino)-7-methylbenzo[d]oxazol-2(3H)-on; 1-492 7-fluor-5-(2-(4-fluor-3-methoxy-5-methylphenylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-493 N2-(3,4-dimethyl-2-fluor)phenyl-5-methyl-N4-(2-oxo-2,3- dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-494 5-(2-(3-methoxy-4-(pyridin-4-yl)phenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-onformatsalt; 1-495 N2-(3-chlor-5-difluormethoxy)phenyl-5-methyl-N4-(2-oxo- 2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-496 5-[2-(3-chlor-4-methoxyphenylamino)-5-methylpyrimidin-4- ylamino]-3H-benzooxazol-2-on; 1-497 5-[2-(3-chlor-5-trifluormethylphenylamino)-5- methylpyrimidin-4-ylamino]-3H-benzooxazol-2-on; 1-498 5-[2-(2-methoxy-5-trifluormethylphenylamino)-5- methylpyrimidin-4-ylamino]-3H-benzooxazol-2-on; 1-499 5-(2-(o-toluidino)-5-methylpyrimidin-4- ylamino)benzo[d]oxazol-2(3H)-on; 1-500 5-(2-(2,3-dimethylphenylamino)-5-methylpyrimidin-4- ylamino)benzo[d]oxazol-2(3H)-on; 1-501 5-(2-(2,5-dimethylphenylamino)-5-methylpyrimidin-4- ylamino)benzo[d]oxazol-2(3H)-on; 1-502 5-(2-(2-ethylphenylamino)-5-methylpyrimidin-4- ylamino)benzo[d]oxazol-2(3H)-on; 1-503 5-(2-(3-ethylphenylamino)-5-methylpyrimidin-4- ylamino)benzo[d]oxazol-2(3H)-on; 1-504 5-(2-(4-ethylphenylamino)-5-methylpyrimidin-4- ylamino)benzo[d]oxazol-2(3H)-on; 1-505 5-(2-(3-fluor-4-(pyridin-3-yl)phenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H) -ontrifluoreddikesyresalt; 1-506 5-(2-(3-methoxy-4-(pyridin-3-yl)phenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-onformatsalt; 1-507 5-(2-(2,4-difluor-3-methoxyphenylamino)-5- methylpyrimidin-4-ylamino)-7-methylbenzo[d]oxazol-2(3H)-on; 1-508 5-(2-(2,4-difluor-3-methoxyphenylamino)-5- methylpyrimidin-4-ylamino)-7-fluorbenzo[d]oxazol-2(3H) -on; 1-509 5-(2-(4-(6-chlorpyridin-3-yl)phenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-ontrifluoracetatsalt; 1-510 5-(2-(4-(6-(3-(dimethylamino)propoxy)pyridin-3- yl)phenylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-ontrifluoracetatsalt; 1-511 5-(2-(4-(6-(3-(dimethylamino)propoxy)pyridin-3- yl)phenylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-ontrifluoracetatsalt; 1-512 5-(5-methyl-2-(4-(6-morpholinopyridin-3- yl)phenylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-ontrifluoracetatsalt; 1-513 5-(2-(2 — fluor-3-methylphenylamino)-5-methylpyrimidin-4- ylamino)benzo[d]oxazol-2(3H)-on; 1-514 5-(2-(2 — fluor-4-methylphenylamino)-5-methylpyrimidin-4- ylamino)benzo[d]oxazol-2(3H)-on; 1-515 5-(2-(2 — fluor-5-methylphenylamino)-5-methylpyrimidin-4- ylamino)benzo[d]oxazol-2(3H)-on; 1-516 N2-(3-difluormethoxy-5-methyl)phenyl-5-methyl-N4-(2-oxo- 2.3- dihydro-l, 3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 1-517 5-methyl-N4-[3-(phosphonooxy)methyl-2-oxo-2,3-dihydro- 1.3- benzoxazol-5-yl]-N2-(3,4,5-trimethyl)phenyl-2,4-pyrimidindiamincalciumsalt; 1-518 5-[5-methyl-2-(2-methyl-3-trifluormethylphenylamino)- pyrimidin-4-ylamino]-3H-benzooxazol-2-on; 1-519 5-(2-(5-acetyl-2-fluorphenylamino)-5-methylpyrimidin-4- ylamino)benzo[d]oxazol-2(3H)-on; 1-520 5-(2-(2-chlorphenylamino)-5-methylpyrimidin-4- ylamino)benzo[d]oxazol-2(3H)-on; 1-521 5-(2-(2-chlor-5-methylphenylamino)-5-methylpyrimidin-4- ylamino)benzo[d]oxazol-2(3H)-on; 1-522 N4-(7-chlor-2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-5- methyl-N2-(3,4,5-trimethyl)phenyl-2,4-pyrimidindiamin; 1-523 5-(2-(2-fluor-5-(1-hydroxyethyl)phenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-524 N4-{3-[bis(1,1-dimethylethoxy)]phosphinyloxymethyl-7- chlor-2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl}-N2-(3,4,5-trimethyl)phenyl-5-methyl-2,4-pyrimidindiamin; 1-525 N4-[7-chlor-3-(phosphonooxy)methyl-2-oxo-2,3-dihydro- 1.3- benzoxazol-5-yl]-5-methyl-N2-(3,4,5-trimethyl)phenyl-2,4-pyrimidindiamin; 1-526 5-methyl-N4-[3-(phosphonooxy)methyl-2-oxo-2,3-dihydro- 1.3- benzoxazol-5-yl]-N2-(3,4,5-trimethyl)phenyl-2,4-pyrimidindiaminmagnesiumsalt; 1-527 5-[2-(4-iod-3,5-dimethylphenylamino)-5-methylpyrimidin- 4-ylamino]-3H-benzooxazol-2-on; 1-528 N4-[7-chlor-3-(phosphonooxy)methyl-2-oxo-2,3-dihydro- 1.3- benzoxazol-5-yl]-5-methyl-N2-(3,4,5-trimethyl)phenyl-2,4-pyrimidindiamin-bis-natriumsalt; 1-529 5-(2-(3,5-dimethoxy-4-methylphenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-530 5-(2-(2-fluor-4,5-dimethylphenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-531 5-methyl-N4-[3-(phosphonooxy)methyl-2-oxo-2,3-dihydro- 1.3- benzoxazol-5-yl]-N2-(3,4,5-trimethyl)phenyl-2,4-pyrimidindiamin-bis-cholinsalt; 1-532 5-(2-(2-fluor-4-methyl-3-(trifluormethyl)phenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-533 5-(2-(2-fluor-5-methoxyphenylamino)-5-methylpyrimidin-4- ylamino)benzo[d]oxazol-2(3H)-on; 1-534 5-(2-(2-fluor-3,4,5-trimethylphenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-535 5-(2-(3-methoxy-4,5-dimethylphenylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 1-536 natrium-(5-(2-(3-methoxy-5-methylphenylamino)-5- methylpyrimidin-4-ylamino)-7-methyl-2-oxobenzo[d]oxazol-3(2H)-yl)methylphosphat; 1-537 N2-(3,4-dimethyl-5-fluor)phenyl-5-methyl-N4- (2-oxo-2,3- dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; I- 538 natrium-(5-(2-(4 — fluor-3-methoxy-5-methylphenylamino)-5-methylpyrimidin-4-ylamino)-2-oxobenzo[d]oxazol-3(2H)- yl)methylphosphat; II- l N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-(6-dimethylaminopyridin-3-yl)-5-methylpyrimidin-2,4-diamin; I1-2 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-(6-((IS, 4R)-5- methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)-pyridin-3-yl)-5-methylpyrimidin-2,4-diamin; II-3 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-(6-(4-methyl-l,4-diazepan-l-yl)pyridin-3-yl)-5-methylpyrimidin-2,4-diamin; II-4 N4-(3-n-propylbenzo[d]oxazol-2(3H)-on-5-yl)-N2-(6-(4- methylpiperazin-l-yl)pyridin-3-yl)-5-methylpyrimidin-2,4-diamin; II-5 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-(6-(4-tert- butyloxycarbonylpiperazin-l-yl)pyridin-3-yl)-5-methylpyrimidin-2,4-diamin; II-6 N4 -(benzo[d]oxazol-2(3H)-on-5-yl)-N2-(6-(4- methylpiperidin-l-yl)pyridin-3-yl)-5-methylpyrimidin-2,4-diamin; II-7 N2-(6-(4-methylpiperazin-l-yl)pyridin-3-yl)-N4-(3- isopropylbenzo[d]oxazol-2(3H)-on-5-yl)-5-methylpyrimidin-2,4-diamin; I1-8 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-(6-(4- trifluormethoxycarbonylpiperazin-1-yl)pyridin-3-yl)-5-methylpyrimidin-2,4-diamin; II-9 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-(6-(4- methoxycarbonylpiperazin-l-yl)pyridin-3-yl)-5-methylpyrimidin- 2,4-diamin; 11-10 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-(6-(piperazin-1- yl)pyridin-3-yl)-5-methylpyrimidin-2,4-diamin; 11-11 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-(6-(3-methyl-4- tert-butoxycarbonylpiperazin-l-yl)pyridin-3-yl)-5-methylpyrimidin-2,4-diamin; 11-12 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-(6-(3- methylpiperazin-l-yl)pyridin-3-yl)-5-methylpyrimidin-2,4-diamin; 11-13 N4-(benzoxazolin-2-on-5-yl)-N2-[2-(4-methylpiperazin-l- yl) pyridin-5-yl]-5-methylpyrimidin-2,4-diamin; 11-14 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-[2-(4- methylpiperazin-l-yl)pyridin-5-yl]-5-fluorpyrimidin-2,4-diamin; 11-15 N4-(benzimidazolin-2-on-5-yl)-N2-[2-(4-methylpiperazin- I- yl)pyridin-5-yl]-5-methylpyrimidin-2,4-diamin; II- 16 N4-(benzimidazolin-2-on-5-yl)-N2-[2-(4-methylpiperazin- I- yl)pyridin-5-yl]-5-fluorpyrimidin-2,4-diamin; II- 17 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-((2- morpholinyl)pyridin-5-yl)-5-methylpyrimidin-2,4-diamin; 11-18 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-((2- morpholinyl)pyridin-5-yl)-5-fluorpyrimidin-2,4-diamin; 11-19 N4-(benzimidazolin-2-on-5-yl)-N2-( (2- morpholinyl)pyridin-5-yl)-5-fluorpyrimidin-2,4-diamin; 11-20 N4-(1,3-dimethylbenzimidazolin-2-on-5-yl)-N2-[2-(4- methylpiperazino)pyridin-5-yl]-5-methylpyrimidin-2,4-diamin; 11-21 N4-(1,3-dimethylbenzimidazolin-2-on-5-yl)-N2-[2- (4- methylpiperazino)pyridin-5-yl]-5-fluorpyrimidin-2,4-diamin; 11-22 N2-(6-(4-methylpiperazin-l-yl)pyridin-3-yl)-N4-(3- methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)-5-methylpyrimidin-2,4-diamin; 11-23 N2-(6-(4-methylpiperazin-l-yl)pyridin-3-yl)-N4-(3- methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)-5-methylpyrimidin-2,4-diamintrifluoracetatsalt; 11-24 N2-(6-(4-methylpiperazin-l-yl)pyridin-3-yl)-N4-(3- methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)-5-fluorpyrimidin- 2,4-diamin; 11-25 6-(5-methyl-2-(6-(4-methylpiperazin-l-yl)pyridin-3- ylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 11-26 N4-(benzoxazolin-2-on-5-yl)-N2-[3-methyl-2-(4- methylpiperazin-l-yl)pyridin-5-yl]-5-methylpyrimidin-2,4-diamin; 11-27 N4-(benzimidazolin-2-on-5-yl)-N2-[3-methyl-2-(4- methylpiperazin-l-yl)pyridin-5-yl]-5-methylpyrimidin-2,4-diamin; 11-28 N4-(benzoxazolin-2-on-5-yl)-N2-[3-methyl-2-((IS,4S)-5- methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)pyridin-5-yl]-5-methylpyrimidin-2,4-diamin; 11-29 N4-(benzoxazolin-2-on-5-yl)-N2-[3-methyl-2-((IS,4S)-5- methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)pyridin-5-yl]-5-fluorpyrimidin-2,4-diamin; 11-30 N4-(benzoxazolin-2-on-5-yl)-N2-[3-methyl-2-(4- methylpiperazin-l-yl)pyridin-5-yl]-5-fluorpyrimidin-2,4-diamin; 11-31 N4-(benzoxazolin-2-on-5-yl)-N2-[2-((IS,4S)-5-methyl-2,5- diazabicyclo[2.2.1]heptan-2-yl)pyridin-5-yl]-5-methylpyrimidin-2,4-diamin; 11-32 N4-(benzoxazolin-2-on-5-yl)-N2-[2-((lS,4S)-2-oxa-5- azabicyclo[2.2.1]heptan-5-yl)pyridin-5-yl]-5-methylpyrimidin- 2.4- diamin; 11-33 N4-(benzoxazolin-2-on-5-yl)-N2-[2-((IS,4S)-5-methyl-2,5- diazabicyclo[2.2.1]heptan-2-yl)pyridin-5-yl]-5-fluorpyrimidin- 2.4- diamin; 11-34 N4-(benzoxazolin-2-on-5-yl)-N2-[2-( (lS,4S)-2-oxa-5- azabicyclo[2.2.1]heptan-5-yl)pyridin-5-yl]-5-fluorpyrimidin- 2.4- diamin; 11-35 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-[2-(1- methylpiperidin-4-yl)aminopyridin-5-yl]-5-methylpyrimidin-2,4-diamin; 11-36 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-[2-(lH-piperidin-4- yl)aminopyridin-5-yl]-5-methylpyrimidin-2,4-diamin; 11-37 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-[2-(8-methyl-8- azabicyclo[3.2.1]oct-3-yl)aminopyridin-5-yl]-5-methylpyrimidin-2,4-diamin; 11-38 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-(4-(8-methyl-2,8- diazabicyclo [3.2.1]octan-2-yl)phenyl)-5-methylpyrimidin-2,4-diamin; 11-39 N4-(benzo[d]oxazolin-2(3H)-on-5-yl)-N2-[3- trifluormethyl-2-(4-methylpiperazin-l-yl)pyridin-5-yl]-5-methylpyrimidin-2,4-diamin; 11-40 N4-(benzoxazolin-2-on-5-yl)-N2-[3-fluor-2-((IS,4S)-5- methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)pyridin-5-yl]-5-methylpyrimidin-2,4-diamin; 11-41 (S)-2-methyl-4-{5-[5-methyl-4-(2-oxo-2,3- dihydrobenzooxazol-5-ylamino)-pyximidin-2-ylamino]-pyridin-2-yl}-piperazin-l-carboxylsyre-tert-butylester; 11-42 5-[5-methyl-2-(pyridin-3-ylamino)-pyrimidin-4-ylamino]- 3H-benzooxazol-2-on; 11-43 5-[2-(6-methansulfonylpyridin-3-ylamino)-5- methylpyrimidin-4-ylamino]-3H-benzooxazol-2-on; 11-44 5-{5-methyl-2-[6-((S)-3-methylpiperazin-l-yl)-pyridin-3- ylamino]-pyrimidin-4-ylamino}-3H-benzooxazol-2-on; 11-45 5-{5-methyl-2-[6-(piperazin-l-carbonyl)-pyridin-3- ylamino]-pyrimidin-4-ylamino}-3H-benzooxazol-2-on; 11-46 5 —{2 —[6-(4-cyclopropylmethylpiperazin-l-carbonyl)- pyridin-3-ylamino]-5-methylpyrimidin-4-ylamino}-3H-benzooxazol-2-on; 11-47 5 —{2 —[6-(4-isobutylpiperazin-l-carbonyl)-pyridin-3- ylamino]-5-methylpyrimidin-4-ylamino}-3H-benzooxazol-2-on; 11-48 5-{3-fluor-5-[5-methyl-4-(2-oxo-2,3-dihydrobenzooxazol- 5-ylamino)-pyrimidin-2-ylamino]-pyridin-2-yl}-hexahydropyrrol[3,4-c]pyrrol-2-carboxylsyre-tert-butylester; 11-49 5-{3-fluor-5-[5-methyl-4-(2-oxo-2,3-dihydrobenzooxazol- 5-ylamino)-pyrimidin-2-ylamino]-pyridin-2-yl}-2,5-diazabicyclo[2.2.1]heptan-2-carboxylsyre-tert-butylester; 11-50 5-{2-[5-fluor-6-(hexahydropyrrol[3,4-c]pyrrol-2-yl)- pyridin-3-ylamino]-5-methylpyrimidin-4-ylamino}-3H-benzooxazol-2-on; 11-51 5-{2-[6-(2,5-diazabicyclo[2.2.1]hept-2-yl)-5-fluor- pyridin-3-ylamino]-5-methylpyrimidin-4-ylamino}-3H-benzooxazol-2-on; 11-52 5—{2—[6—(5-cyclopropylmethylhexahydropyrrol[3,4- c]pyrrol-2-yl)-5-fluorpyridin-3-ylamino]-5-methylpyrimidin-4-ylamino}-3H-benzooxazol-2-on; 11-53 5—{2—[6—(5-cyclopropancarbonylhexahydropyrrol[3,4- c]pyrrol-2-yl)-5-fluorpyridin-3-ylamino]-5-methylpyrimidin-4-ylamino}-3H-benzooxazol-2-on; 11-54 5—[2—[6—(5-cyclopropylmethyl-2,5- diazabicyclo[2.2.1]hept-2-yl)-5-fluor-pyridin-3-y1amino]-5-methylpyrimidin-4-ylamino}-3H-benzooxazol-2-on; 11-55 (R)—5—(2—(6—(3,4-dimethylpiperazin-l-yl)pyridin-3- ylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H) -on; 11-56 (R)-5-(2-(6-(4-(cyclopropylmethyl)-3-methylpiperazin-l- yl)pyridin-3-ylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 11-57 (R)-5-(5-methyl-2-(6-(3-methyl-4-(2,2,2- trifluoracetyl)piperazin-l-yl)pyridin-3-ylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 11-58 (R)-diethyl-2-methyl-4-(5-(5-methyl-4-(2-oxo-2,3- dihydrobenzo[d]oxazol-5-ylamino)pyrimidin-2-ylamino)pyridin-2-yl)piperazin-l-ylphosphonat; 11-59 5-(2-(6-(4,4-difluorpiperidin-l-yl)pyridin-3-ylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 11-60 5-(2-(6-(4,4-dimethylpiperidin-l-yl)pyridin-3-ylamino)- 5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 11-61 5-(2-(6-(3,8-diazabicyclo[3.2.1]octan-3-yl)-5- methylpyridin-3-ylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 11-62 5-(5-methyl-2-(5-methyl-6-(8-acetyl)-3,8- diazabicyclo[3.2.1]octan-3-yl)pyridin-3-ylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 11-63 5-(5-methyl-2-(5-methyl-6-(8-(2,2,2-trifluoracetyl)-3,8- diazabicyclo[3.2.1]octan-3-yl)pyridin-3-ylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 11-64 5-(5-methyl-2-(5-methyl-6-(8-methyl-3,8- diazabicyclo[3.2.1]octan-3-yl)pyridin-3-ylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 11-65 tert-butyl-3-(3-methyl-5-(5-methyl-4-(2-oxo-2,3- dihydrobenzo[d]oxazol-5-ylamino)pyrimidin-2-ylamino)pyridin-2-yl)-8-azabicyclo[3.2.1]octan-8-carboxylat; 11-66 5-(2-(6-(8-azabicyclo[3.2.1]octan-3-yl)-5-methylpyridin- 3-ylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 11-67 5-(2-(6-(8-(cyclopropylmethyl)-8-azabicyclo[3.2.1]octan- 3-yl)-5-methylpyridin-3-ylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 11-68 methyl-3-(3-methyl-5-(5-methyl-4-(2-oxo-2,3- dihydrobenzo[d]oxazol-5-ylamino)pyrimidin-2-ylamino)pyridin-2-yl)-8-azabicyclo[3.2.1]octan-8-carboxylat; 11-69 5-(5-methyl-2-(5-methyl-6-(8-(2,2,2-trifluoracetyl)-8- azabicyclo[3.2.1]octan-3-yl)pyridin-3-ylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 11-70 (R)-5-(2-(6-(4-isopropyl-3-methylpiperazin-l-yl)pyridin- 3-ylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H) -on; 11-71 5-(5-methyl-2-(6-(pyrrolidin-l-yl)pyridin-3- ylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 11-72 7-methyl-5-(5-methyl-2-(6-(4-methylpiperazin-l- yl)pyridin-3-ylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 11-73 7-methyl-5-(5-methyl-2-(6-morpholinopyridin-3- ylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H) -on; 11-74 5-(2-(6-(cyclopropylmethylamino)pyridin-3-ylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 11-75 7-fluor-5-(5-methyl-2-(6-(4-methylpiperazin-l- yl)pyridin-3-ylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 11-76 7-fluor-5-(5-methyl-2-(6-morpholinopyridin-3- ylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 11-77 5-(2-(5-brompyridin-3-ylamino)-5-methylpyrimidin-4- ylamino)benzo[d]oxazol-2(3H)-on; 11-79 N-(5-(5-methyl-4-(3-methyl-2-oxo-2,3- dihydrobenzo[d]oxazol-5-ylamino)pyrimidin-2-ylamino)pyridin-2-yl) methansuitonamid; 11-80 5-(2-(6-(3-(dimethylamino)pyrrolidin-l-yl)pyridin-3- ylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 11-81 N-(1-(5-(5-methyl-4-(2-oxo-2,3-dihydrobenzo[d]oxazol-5- ylamino)pyrimidin-2-ylamino)pyridin-2-yl)pyrrolidin-3-yl)acetamid; 11-82 5-(2-(6-(3-(diethylamino)pyrrolidin-l-yl)pyridin-3- ylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 11-83 2,2,2-trifluor-N-(l-(5-(5-methyl-4- (2-oxo-2,3- dihydrobenzo[d]oxazol-5-ylamino)pyrimidin-2-ylamino)pyridin-2-yl) pyrrolidin-3-yl)acetamid; 11-84 5-(5-methyl-2-(6-(3-morpholinopyrrolidin-l-yl)pyridin-3- ylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 11-85 5-(2-(6-(4-methylpiperazin-l-yl)pyridin-3-ylamino)-5- (trifluormethyl)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 11-86 tert-butyl-1-(5-(5-methyl-4-(2-oxo-2,3- dihydrobenzo[d]oxazol-5-ylamino)pyrimidin-2-ylamino)pyridin-2-yl) pyrrolidin-3-ylcarbamat; 11-87 (S)-tert-butylmethyl(1-(5-(5-methyl-4-(2-oxo-2,3- dihydrobenzo[d]oxazol-5-ylamino)pyrimidin-2-ylamino)pyridin-2-yl)piperidin-3-yl)carbamat; 11-88 (R)-5-(5-methyl-2-(6-(3-(methylamino)piperidin-1- yl)pyridin-3-ylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 11-89 (R)-5-(2-(6-(3-(dimethylamino)pyrrolidin-l-yl)pyridin-3- ylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 11-90 (S) -5-(2-(6-(3-(dimethylamino)pyrrolidin-l-yl)pyridin-3- ylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 11-91 (R)-tert-butylmethyl(1-(5-(5-methyl-4-(2-oxo-2,3- dihydrobenzo[d]oxazol-5-ylamino)pyrimidin-2-ylamino)pyridin-2-yl)piperidin-3-yl)carbamat; 11-92 (R)-5-(5-methyl-2-(6-(3-(methylamino)piperidin-1- yl)pyridin-3-ylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 11-94 5-(2-(6-(3-(cyclopropylmethylamino)pyrrolidin-1- yl)pyridin-3-ylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 11-95 (5) -5-(2-(6-((l-benzylpiperidin-3- yl)(methyl)amino)pyridin-3-ylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 11-96 1-ethyl-3-(1-(5-(5-methyl-4-(2-oxo-2,3- dihydrobenzo[d]oxazol-5-ylamino)pyrimidin-2-ylamino)pyridin-2-yl)pyrrolidin-3-yl)urea; 11-97 l-tert-butyl-3-(1-(5-(5-methyl-4-(2-oxo-2,3- dihydrobenzo[d]oxazol-5-ylamino)pyrimidin-2-ylamino)pyridin-2-yl)pyrrolidin-3-yl)urea; 11-98 1-benzyl-3-(1-(5-(5-methyl-4-(2-oxo-2,3- dihydrobenzo[d]oxazol-5-ylamino)pyrimidin-2-ylamino)pyridin-2-yl)pyrrolidin-3-yl)urea; 11-99 (S)-5-(2-(6-(l-benzylpiperidin-3-ylamino)pyridin-3- ylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H) -on; 11 — 10 O (S) -5-(2-(6-((l-benzylpiperidin-3- yl)(methyl)amino)pyridin-3-ylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 11-101 N-(1-(5-(5-methyl-4-(2-oxo-2,3-dihydrobenzo[d]oxazol-5-ylamino)pyrimidin-2-ylamino)pyridin-2-yl)pyrrolidin-3-yl)cyclopropancarboxamid; 11-102 N-(1-(5-(5-methyl-4-(2-oxo-2,3-dihydrobenzo[d]oxazol-5-ylamino)pyrimidin-2-ylamino)pyridin-2-yl)pyrrolidin-3-yl)pivalamid; 11-103 (S)-5-(5-methyl-2-(6-(methyl(piperidin-3- yl)amino)pyridin-3-ylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 11-104 (S)-5-(5-methyl-2-(6-(piperidin-3-ylamino)pyridin-3- ylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 11-105 (S)-5-(2-(6-(l-benzylpiperidin-3-ylamino)pyridin-3- ylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 11-106 (R)-5-(2-(6-((l-benzylpiperidin-3- yl)(methyl)amino)pyridin-3-ylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 11-107 (R)-5-(5-methyl-2-(6-(piperidin-3-ylamino)pyridin-3- ylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 11-108 (R)-5-(5-methyl-2-(6-(methyl(piperidin-3- yl)amino)pyridin-3-ylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 11-109 N4-(benzo[d]oxazolin-2(3H)-one-5-yl)-5-methyl-N2-[2- ((IS,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)-3-trifluormethylpyridin-5-yl]-2,4-pyrimidindiamin; 11-110 N4-(benzo[d]oxazolin-2(3H)-one-5-yl)-N2-[2 - (4- ethylpiperazin-l-yl)-3-trifluormethylpyridin-5-yl]-5-methyl- 2.4- pyrimidindiamin; 11-111 N4-(benzo[d]oxazolin-2(3H)-one-5-yl)-N2-[3-fluor-2 - (4- methylpiperazin-l-yl)pyridin-5-yl]-5-methyl-2,4-pyrimidindiamin; 11-112 N4-(benzo[d]oxazolin-2(3H)-one-5-yl)-N2-{2-[(8S)-1,4- diazabicyclo[4.3.0]nonan-l-yl]-3-fluorpyridin-5-yl}-5-methyl- 2.4- pyrimidindiamin; 11-113 N4-(benzo[d]oxazolin-2(3H)-one-5-yl)-N2-12-[(8R)-1,4-diazabicyclo[4.3.0]nonan-l-yl]-3-fluorpyridin-5-yl}-5-methy1- 2,4-pyrimidindiamin; 11-114 N4-(benzo[d]oxazolin-2(3H)-one-5-yl)-N2-[2-(4- ethylpiperazin-l-yl)-3-fluorpyridin-5-yl]-5-methyl-2,4-pyrimidindiamin; 11-115 N4-(benzo[d]oxazolin-2(3H)-one-5-yl)-N2-[3-cyano-2- ((IS,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)pyridin-5-yl]-5-methyl-2,4-pyrimidindiamme; 11-116 N2-[3-chlor-2-(4-methylpiperazino)pyridin-5-yl]-5- methyl-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 11-117 5-methyl-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-N2-[2-(1,3,5-trimethyl-3,7-diazabicyclo[3.3.1]nonan-7-yl)pyridin-5-yl]-2,4-pyrimidindiamin; 11-118 N2-[3-chlor-2-(3-ethyl-3,7-diazabicyclo[3.3.0]octan-7- yl)pyridin-5-yl]-5-methyl-N4-(2-oxo-2,3-dihydro-l, 3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 11-119 N2-[2-(3-ethyl-3,7-diazabicyclo[3.3.0]octan-7-yl)-3- trifluormethylpyridin-5-yl]-5-methyl-N4-(2-oxo-2,3-dihydro- 1.3- benzoxazol-5-yl)-2,4-pyrimidindiamin; 11-120 5-methyl-N2-[2-(3-methyl-3,7-diazabicyclo[3.3.0]octan- 7-yl)pyridin-5-yl]-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl) - 2.4- pyrimidindiamin; 11-121 5-methyl-N2-[2-(octahydroisoindol-l-yl)pyridin-5-yl]- N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 11-122 N2-[3-chlor-2-(octahydroisoindol-l-yl)pyridin-5-yl]-5- methyl-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 11-123 N2-(2-methoxypyridin-5-yl)-5-methyl-N4-(2-oxo-2,3- dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 11-124 N2-[2-(S-l,4-diazabicyclo[4.3.0]nonan-4-yl)-3- trifluormethylpyridin-5-yl]-5-methyl-N4-(2-oxo-2,3-dihydro- 1,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 11-125 N2-[2-(l,4-diazabicyclo[3.2.2]nonan-4-yl)-3- fluorpyridin-5-yl]-5-methyl-N4-(2-oxo-2,3-dihydro-l, 3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 11-126 N2-[2-(4R-hydroxy-2-methylidene-pyrrolidin-l- yl)pyridin-5-yl]-5-methyl-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 11-127 5-methyl-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-N2-[2-(cis-3,4,5-trimethylpiperazino)pyridin-5-yl]-2,4-pyrimidindiamin; 11-128 N2-[2-(l,4-diazabicyclo[4.4.0]decan-4-yl)pyridin-5-yl]-5-methyl-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl) -2,4-pyrimidindiamin; 11-129 5-methyl-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-Niti- (trans-2,4,5-trimethylpiperazino)pyridin-5-yl]-2,4-pyrimidindiamin; 11-130 N2-[2-(trans-2,5-dimethylpiperazino)pyridin-5-yl]-5- methyl-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl) -2,4-pyrimidindiamin; 11-131 N2-[2-(cis-3,5-dimethylpiperazino)pyridin-5-yl]-5- methyl-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl) -2,4-pyrimidindiamin; 11-132 N2-[2-(R-l,4-diazabicyclo[4.3.0]nonan-4-yl)pyridin-5-yl]-5-methyl-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 11-133 5-methyl-N2-[2-(7-methyl-2,7-diazaspiro[4.4]nonan-2- yl)pyridin-5-yl]-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl) - 2,4-pyrimidindiamin; 11-134 5-methyl-N2-[2-(3S-methylmorpholino)pyridin-5-yl]-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 11-135 5-methyl-N2-[2-(2R-methylmorpholino)pyridin-5-yl]-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 11-136 N2-[2-(4-isopropylpiperazino)pyridin-5-yl]-5-methyl-N4- (2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 11-137 N2-[2-(3-N,N-dimethylamino-8-azabicyclo[3.2.1]octan-8- yl)pyridin-5-yl]-5-methyl-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 11-138 5-methyl-N2-[2-(2S-methylmorpholino)pyridin-5-yl]-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 11-139 5-methyl-N2-{2-[(IR,4R)-2-oxa-5- azabicyclo[2.2.1]heptan-5-yl]pyridin-5-yl}-N4-(2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 11-140 N2-(2,3-dimethoxypyridin-5-yl)-5-methyl-N4-(2-oxo-2,3- dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 11-141 N2-(2-methoxy-3-methylpyridin-5-yl)-5-methyl-N4-(2-oxo- 2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 11-142 N2-[2-(2-hydroxy)ethoxypyridin-5-yl]-5-methyl-N4-(2- oxo-2,3-dihydro-l, 3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 11-143 N2-[4-methyl-2-(4-methylpiperazino)pyridin-5-yl]-5- methyl-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl) -2,4-pyrimidindiamin; 11-144 N2-(2-isopropoxypyridin-5-yl)-5-methyl-N4-(2-oxo-2,3- dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 11-145 N2-[2-(2-methoxy)ethoxypyridin-5-yl]-5-methyl-N4-(2- oxo-2,3-dihydro-l, 3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 11-146 N2-[2-(1-aminocarbonyl-l-methyl)ethoxypyridin-5-yl]-5- methyl-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl) -2,4-pyrimidindiamin; 11-147 N2-(2-rnethoxy-3-trifluormethylpyridin-5-yl)-5-methyl- N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 11-148 N2-[2-(3-hydroxy)propoxypyridin-5-yl]-5-methyl-N4-(2- oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 11-149 N2-[2-(3-methoxy)propoxypyridin-5-yl]-5-methyl-N4-(2- oxo-2,3-dihydro-l, 3-benzoxazol-5-yl)-2,4-pyrimidindiamin; 11-150 5-(2-(6-(l,4-diazabicyclo[3.2.2]nonan-4-yl)-5- chlorpyridin-3-ylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; 11-151 5-[5-methyl-4-(2-oxo-2,3-dihydrobenzooxazol-5-ylamino)- pyrimidin-2-ylamino]-pyridin-2-carboxylsyrecyclobutylamid; 11-152 N2-(S-methoxypyridin-3-yl)-5-methyl-N4-(2-oxo-2,3- dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; II- 153 N2-(2,3-dimethylpyridin-5-yl)-5-methyl-N4-(2-oxo-2,3- dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; III- l N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-(isoindolin-5-yl)-5-methylpyrimidin-2,4-diamin; II1-2 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2- (2Hydroxyisoindolin-5-yl)-5-methylpyrimidin-2,4-diamin; II1-3 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-(2-tert- butoxoxycarbonylisoindolin-5-yl)-5-methylpyrimidin-2,4-diamin; II1-4 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-(2- methylisoindolin-5-yl)-5-methylpyrimidin-2,4-diamin; III-5 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-(2-ethylisoindolin-5-yl)-5-methylpyrimidin-2,4-diamin; III-6 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-(2-n- propylisoindolin-5-yl)-5-methylpyrimidin-2,4-diamin; II1-7 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-(2- cyclopropylmethylylisoindolin-5-yl)-5-methylpyrimidin-2,4-diamin; II1-8 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-(2- isobutylisoindolin-5-yl)-5-methylpyrimidin-2,4-diamin; 111-9 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2 - (2- isopentylisoindolin-5-yl)-5-methylpyrimidin-2,4-diamin; III-10 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2 - (2- cyclopentylmethylisoindolin-5-yl)-5-methylpyrimidin-2,4-diamin; III-ll N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-(2- (bicyclo[2.2.1]heptan-2-ylmethyl)isoindolin-5-yl )-5-methylpyrimidin-2,4-diamin; III-12 5-[2-(2-acetyl-2,3-dihydro-lH-isoindol-5-ylamino)-5- methylpyrimidin-4-ylamino]-3H-benzooxazol-2-on; II1-13 N-{2-[2-(2,2-dimethylpropionyl)-2,3-dihydro-1H- isoindol-5-ylamino]-5-methylpyrimidin-4-yl}-N-[3-(2,2-dimethylpropionyl)-2-oxo-2,3-dihydrobenzooxazol-5-yl]-2,2-dimethylpropionamid; III- 14 5-[2-(2-methansulfonyl-2,3-dihydro-lH-isoindol-5- ylamino)-5-methylpyrimidin-4-ylamino]-3H-benzooxazol-2-on; IV- 1 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-(7-(pyrrolidin-1- yl)-6, 7, 8, 9-tetrahydro-5H-benzo[7]annulen-2-yl)-5-methylpyrimidin-2,4-diamin; IV-2 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-(6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-on-3-yl)-5-methylpyrimidin-2,4-diamin; IV-3 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2 - (6-(4- methylpiperazin-l-yl)pyridazin-3-yl)-5-methylpyrimidin-2,4-diamin; IV-4 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-(lH-indazol-6-yl)-5-methylpyrimidin-2,4-diamin; IV-5 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-(1,2-benzisoxazol-6- yl)-5-methylpyrimidin-2,4-diamin; IV-6 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-(lH-indazol-5-yl) -5-methylpyrimidin-2,4-diamin; IV-7 N4-(benzo[d]oxazol-2 (3H)-on-5-yl)-N2- [2- (piperazino)pyridin-4-yl]-5-methylpyrimidin-2,4-diamin; IV-8 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2 - [2-(4- methylpiperazino)pyridin-4-yl]-5-methylpyrimidin-2,4-diamin; IV-9 N4-(benzo[d]oxazol-2(3H)-on-5-yl)-N2-(3-methyl-1,2- benzisoxazol-5-yl)-5-methylpyrimidin-2,4-diamin; IV-10 (Z)-2-methyl-9-[5-methyl-4-(2-oxo-2,3- dihydrobenzooxazol-5-ylamino)-pyrimidin-2-ylamino]-3, 6-dihydro-2H-benzo[c]azocin-l-on; IV-11 5—[2—(2,2-difluorbenzo[1,3]dioxol-4-ylamino)-5- methylpyrimidin-4-ylamino]-3H-benzooxazol-2-on; IV-12 5-[2-(9-isopropylamino-6,7,8,9-tetrahydro-5H- benzocyclohepten-2-ylamino)-5-methylpyrimidin-4-ylamino]-3H-benzooxazol-2-on; IV-13 5 —{2 —[9-(3-diethylaminopyrrolidin-l-yl)-6,7,8,9- tetrahydro-5H-benzocyclohepten-2-ylamino]-5-methylpyrimidin-4-ylamino}-3H-benzooxazol-2-on; IV-14 2-methyl-9-[5-methyl-4-(2-oxo-2,3-dihydrobenzooxazol-5- ylamino)-pyrimidin-2-ylamino]-3,4,5,6-tetrahydro-2H-benzo[c]azocin-l-on; IV-15 6-[5-methyl-4-(2-oxo-2,3-dihydrobenzooxazol-5-ylamino)- pyrimidin-2-ylamino]-3,4-dihydro-2H-isoquinolin-l-on; IV-16 5-[2-(2,2-dioxo-lH-benzo[e][l,3,4]oxathiazin-7-ylamino)- 5-methylpyrimidin-4-ylamino]-3H-benzooxazol-2-on; IV-17 5-[2-(2,2-dimethylbenzo[1,3]dioxol-5-ylamino)-5- methylpyrimidin-4-ylamino]-3H-benzooxazol-2-on; IV-18 (Z) -5-(5-methyl-2-(l-oxo-2,3-dihydro-lH-benzo[c]azepin- 7-ylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; IV-19 (Z) -5-(5-methyl-2-(2-methyl-l-oxo-2,3-dihydro-lH- benzo[c]azepin-7-ylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; IV-20 (Z) -5-(5-methyl-2-(2-methyl-l-oxo-2,3-dihydro-lH- benzo[c]azepin-7-ylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; IV-21 5-(5-methyl-2-(2-methyl-l-oxo-2,3,4,5-tetrahydro-lH- benzo[c]azepin-7-ylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; IV-22 5,5'-(5-methylpyrimidin-2,4- diyl)bis(azanediyl)dibenzo[d]oxazol-2(3H)-on; IV-23 5-(5-methyl-2-(2-oxo-2,3,4,5-tetrahydro-lH- benzo[b]azepin-8-ylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; IV-24 5-(5-methyl-2-(2-oxo-l,2,3,4-tetrahydroquinolin-7- ylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; IV-25 6-(5-methyl-4-(2-oxo-2,3-dihydrobenzo[d]oxazol-5- ylamino)pyrimidin-2-ylamino)-2H-benzo[b][1,4]oxazin-3(4H)-on; IV-26 5-(2-(3,3-dimethyl-2-oxoindolin-6-ylamino)-5- methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; IV-27 5-(5-methyl-2-(l-methyl-2-oxoindolin-5- ylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2 (3H)-on; IV-28 5-(5-methyl-2-(l-methyl-2-oxo-2,3-dihydro-lH- benzo[d]imidazol-5-ylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; IV-29 5-(5-methyl-2-(2-oxo-2,3-dihydro-lH-benzo[d]imidazol-5- ylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; IV-30 5-(5-methyl-2-(l-methyl-2-oxo-2,3,4,5-tetrahydro-lH- benzo[b]azepin-8-ylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; IV-31 5-(5-methyl-2-(2-oxo-2,3,4,5-tetrahydro-lH- benzo[b]azepin-7-ylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; IV-32 7-(5-methyl-4-(2-oxo-2,3-dihydrobenzo[d]oxazol-5- ylamino)pyrimidin-2-ylamino)-2H-benzo[b] [1,4]oxazin-3(4H)-on; IV-33 5-(5-methyl-2-(2-oxo-l,2,3,4-tetrahydroquinolin-6- ylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H) -on; IV-34 5-(5-methyl-2-(l-methyl-2-oxo-2,3,4,5-tetrahydro-lH- benzo[b]azepin-7-ylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on; IV-35 5-methyl-N2-(3,4-methylendioxy)phenyl-N4-(2-oxo-2,3- dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; IV-36 N2-(2,2-difluor-2H-l,3-benzodioxol-5-yl)-5-methyl-N4-(2- oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; IV-37 N2-(3,4-ethylendioxy)phenyl-5-methyl-N4-(2-oxo-2,3- dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; IV-38 N2-(2,2-dimethyl-2H-l,3-benzodioxol-5-yl)-5-methyl-N4- (2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; IV-39 N2-[spiro(2,l'-cyclohexan)-1,3-benzodioxol-5-yl]-5- methyl-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl) -2,4-pyrimidindiamin; IV-40 N2-(1, 3-dimethyl-lH-pyrazolo[3,4-b]pyridin-5-yl)-5- methyl-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl) -2,4-pyrimidindiamin; IV-41 5-methyl-N2-(l-methylindazol-6-yl)-N4-(2-oxo-2,3- dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; IV-42 5-methyl-N2-(l-methylindazol-5-yl)-N4-(2-oxo-2,3- dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; IV-43 5-methyl-N2-(3-methylisoxazolo[5,4-b]pyridin-5-yl)-N4- (2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; IV-44 N2-[4-(2-methoxyethyl)-2H-1,4-benzoxazin-3(4H)-one-7- yl]-5-methyl-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; IV-45 N2-[2,2-dimethyl-4-(2-methoxyethyl)-2H-pyrido[3,2- b][1,4]oxazin-3(4H)-one-7-yl]-5-methyl-N4-(2-oxo-2,3-dihydro- 1,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; IV-46 5-methyl-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-N2- (2H-pyrido[3,2-b][1,4]oxazin-3(4H)-on-7-yl)-2,4-pyrimidindiamin; IV-47 5-methyl-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-N2- (2H-pyrido[3,2-b][1,4]oxazin-3(4H)-on-6-yl)-2,4-pyrimidindiamin; IV-48 5-methyl-N2-(3-methylindazol-6-yl)-N4-(2-oxo-2,3- dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; IV-49 5-methyl-N2-(3-methylindazol-5-yl)-N4-(2-oxo-2,3- dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; IV-50 N2-[2,2-dimethyl-2H-1,4-benzoxazin-3(4H)-on-7-yl]-5- methyl-N4-(2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; IV-51 5-(5-methyl-2-(6-methylpyridin-2-ylamino)pyrimidin-4- ylamino)benzo[d]oxazol-2(3H)-on; IV-52 5-(5-methyl-2-(5-methylpyridin-2-ylamino)pyrimidin-4- ylamino)benzo[d]oxazol-2(3H)-on; IV-53 5-[2-(isoquinolin-6-ylamino)-5-methylpyrimidin-4- ylamino]-3H-benzooxazol-2-on; IV-54 5-[5-methyl-2-(naphthalen-2-ylamino)-pyrimidin-4- ylamino]-3H-benzooxazol-2-on; IV-55 5-[2-(4-methoxynaphthalen-2-ylamino)-5-methylpyrimidin- 4-ylamino]-3H-benzooxazol-2-on; IV-56 5-[2-(4-hydroxynaphthalen-2-ylamino)-5-methylpyrimidin- 4-ylamino]-3H-benzooxazol-2-on; IV-57 5-[2-(isoquinolin-7-ylamino)-5-methylpyrimidin-4- ylamino]-3H-benzooxazol-2-on; IV-58 N2-(4-methoxypyridin-2-yl)-5-methyl-N4-(2-oxo-2,3- dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidindiamin; IV-59 5-[5-methyl-2-(2,4,6-trifluorphenylamino)-pyrimidin-4- ylamino]-3H-benzooxazol-2-on; IV-60 5-(2-(2,6-dimethylphenylamino)-5-methylpyrimidin-4- ylamino)benzo[d]oxazol-2(3H)-on; IV-61 5-[5-methyl-2-(2,4,6-trimethylphenylamino)-pyrimidin-4- ylamino]-3H-benzooxazol-2-on; IV-62 5-(2-(2-fluor-6-methylphenylamino)-5-methylpyrimidin-4- ylamino)benzo[d]oxazol-2(3H)-on; IV-63 N2-(3-fluorpyridin-4-yl)-5-methyl-N4-(2-oxo-2,3-dihydro- 1.3- benzoxazol-5-yl)-2,4-pyrimidindiamin; eller IV-64 N2-(3-fluorpyridin-4-yl)-5-methyl-N4-(2-oxo-2,3-dihydro- 1.3- benzoxazol-5-yl)-2,4-pyrimidindiamintrifluoreddikesyresalt.
14. Forbindelse ifølge krav 1, som er 5-methyl-N4-[3- (phosphonooxy)methyl-2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl]-N2-(3,4,5-trimethyl)phenyl-2,4-pyrimidindiamin eller et farmaceutisk acceptabelt salt deraf, fortrinsvis 5-methyl-N4-[3-(phosphonooxy)methyl-2-oxo-2,3-dihydro-l,3-benzoxazol-5- yl]-N2-(3,4,5-trimethyl)phenyl-2,4-pyrimidindiamin-bis-natriumsalt.
15. Forbindelse ifølge krav 1, hvor forbindelsen er N2-(3-methoxy-5-trifluormethyl) phenyl-5-methyl-N4-[3- (phosphonooxy)methyl-2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl]- 2.4- pyrimidindiamin eller et farmaceutisk acceptabelt salt deraf, fortrinsvis N2-(3-methoxy-5-trifluormethyl)phenyl-5-methyl-N4-[3-(phosphonooxy)methyl-2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl]-2,4-pyrimidindiamin-bis-natriumsalt.
16. Forbindelse ifølge krav 1, hvor forbindelsen er 5-(2-(3-methoxy-4,5-dimethylphenylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on eller et farmaceutisk acceptabelt salt deraf.
17. Forbindelse ifølge krav 1, hvor forbindelsen er (5-(2-(4-fluor-3-methoxy-5-methylphenylamino)-5-methylpyrimidin-4-ylamino)-2-oxobenzo[d]oxazol-3(2H) - yl)methyldihydrogenphosphat, 5-(2-(4-fluor-3-methoxy-5- methylphenylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on eller et farmaceutisk acceptabelt salt deraf, fortrinsvis natrium-(5-(2-(4-fluor-3-methoxy-5- methylphenylamino)-5-methylpyrimidin-4-ylamino)-2-oxobenzo[d]oxazol-3(2H)-yl)methylphosphat eller 5-(2-(4-fluor-3-methoxy-5-methylphenylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-on.
18. Farmaceutisk sammensætning, der omfatter forbindelsen ifølge et hvilket som helst af kravene 1-17.
19. Forbindelsen ifølge et hvilket som helst af kravene 1-17 eller farmaceutisk sammensætning ifølge krav 18 til anvendelse til behandling af en JAK-kinasemedieret sygdom, allograft-transplantat-afstødning hos en transplantatrecipient, T- cellemedieret autoimmun sygdom eller en sygdom og/eller forstyrrelse i øjet.
DK10701189.2T 2009-01-23 2010-01-22 Sammensætninger og fremgangsmåder til hæmning af jak-reaktionsvejen DK2389372T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14705909P 2009-01-23 2009-01-23
US24163009P 2009-09-11 2009-09-11
PCT/US2010/021856 WO2010085684A1 (en) 2009-01-23 2010-01-22 Compositions and methods for inhibition of the jak pathway

Publications (1)

Publication Number Publication Date
DK2389372T3 true DK2389372T3 (da) 2015-12-14

Family

ID=42091548

Family Applications (2)

Application Number Title Priority Date Filing Date
DK12195147.9T DK2565193T3 (da) 2009-01-23 2010-01-22 Sammensætninger og fremgangsmåder til hæmning af JAK-signalvejen
DK10701189.2T DK2389372T3 (da) 2009-01-23 2010-01-22 Sammensætninger og fremgangsmåder til hæmning af jak-reaktionsvejen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK12195147.9T DK2565193T3 (da) 2009-01-23 2010-01-22 Sammensætninger og fremgangsmåder til hæmning af JAK-signalvejen

Country Status (24)

Country Link
US (13) US8324200B2 (da)
EP (2) EP2389372B1 (da)
JP (1) JP5802136B2 (da)
KR (1) KR101762967B1 (da)
CN (1) CN102356075B (da)
AU (1) AU2010206683B2 (da)
BR (1) BRPI1006942A2 (da)
CA (1) CA2749217C (da)
DK (2) DK2565193T3 (da)
EA (1) EA022802B1 (da)
ES (2) ES2555491T3 (da)
HK (2) HK1183023A1 (da)
HR (2) HRP20140454T1 (da)
HU (1) HUE026315T2 (da)
IL (1) IL214208A (da)
MX (1) MX2011007750A (da)
NZ (1) NZ594323A (da)
PE (2) PE20150621A1 (da)
PL (2) PL2565193T3 (da)
PT (2) PT2565193E (da)
SG (2) SG2014005318A (da)
SI (2) SI2389372T1 (da)
SM (2) SMT201400071B (da)
WO (1) WO2010085684A1 (da)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2608367C (en) 2005-06-08 2014-08-19 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US20070203161A1 (en) * 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
EP2389372B1 (en) * 2009-01-23 2015-09-09 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
CA2766088C (en) 2009-06-25 2017-06-13 Alkermes, Inc. Heterocyclic compounds for the treatment of neurological and psychological disorders
CA2766033C (en) * 2009-06-25 2016-09-20 Alkermes, Inc. Prodrugs of nh-acidic compounds
RU2672100C2 (ru) * 2010-07-28 2018-11-12 Райджел Фармасьютикалз, Инк. Композиции и способы ингибирования пути jak
KR101594002B1 (ko) 2010-10-06 2016-02-15 글락소스미스클라인 엘엘씨 Ｐｉ３ 키나제 억제제로서의 벤즈이미다졸 유도체
CA2830882C (en) 2011-03-22 2021-03-16 Dinesh Barawkar Substituted fused tricyclic compounds, compositions and medicinal applications thereof
PL2693881T3 (pl) 2011-04-01 2020-03-31 University Of Utah Research Foundation Podstawione analogi N-fenylopirymidyno-2-aminy jako inhibitory kinazy AXL
JP6147727B2 (ja) 2011-04-01 2017-06-14 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション チロシン受容体キナーゼｂｔｋ阻害剤としての置換ｎ−（３−（ピリミジン−４−イル）フェニル）アクリルアミド類似体
EP2696869B1 (en) * 2011-04-12 2017-08-23 Rigel Pharmaceuticals, Inc. Methods for inhibiting allograft rejection
EP2554544A1 (en) * 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
ES2715562T3 (es) 2011-12-15 2019-06-04 Alkermes Pharma Ireland Ltd Profármacos de compuestos de amina secundaria
WO2013173506A2 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
MX361499B (es) * 2012-08-17 2018-12-06 Concert Pharmaceuticals Inc Baricitinib deuterado.
IN2015DN02008A (da) 2012-09-21 2015-08-14 Advinus Therapeutics Ltd
CN104822664B (zh) 2012-10-04 2017-01-18 犹他大学研究基金会 作为酪氨酸受体激酶btk抑制剂的取代的n‑(3‑(嘧啶‑4‑基)苯基)丙烯酰胺类似物
KR20150067298A (ko) 2012-10-04 2015-06-17 유니버시티 오브 유타 리서치 파운데이션 티로신 수용체 키나아제 btk 억제제로서의 치환된 n-(3-(피리미딘-4-일)페닐)아크릴아미드 유사체
CN103788066A (zh) * 2012-10-31 2014-05-14 韩冰 一类保护移植器官的化合物及其用途
CA2899281C (en) * 2013-01-25 2022-05-31 Rigel Pharmaceuticals, Inc. Pyrimidinediamine compounds for use in treating or preventing autoimmune alopecia
CN108997225A (zh) 2013-03-14 2018-12-14 特雷罗药物股份有限公司 Jak2和alk2抑制剂及其使用方法
EP2983674A4 (en) 2013-04-08 2017-05-10 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
US9549988B2 (en) 2013-06-09 2017-01-24 RJS Biologics Pharmaceutical compounds targeted by MIF affinity-tethered moieties
US9556148B2 (en) 2013-08-07 2017-01-31 Cadila Healthcare Limited N-cyanomethylamides as inhibitors of janus kinase
CN105017159B (zh) * 2014-04-28 2019-05-17 四川大学 5-氟-2,4-二取代氨基嘧啶衍生物及其制备方法和用途
US10314942B2 (en) * 2014-06-30 2019-06-11 Bacterin International, Inc. Manufacture of biomaterial implants via three-dimensional printing technology
WO2016100452A2 (en) * 2014-12-17 2016-06-23 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2017007658A1 (en) * 2015-07-07 2017-01-12 Rigel Pharmaceuticals, Inc. A combination for immune mediated cancer treatment
LT3380465T (lt) 2015-11-26 2020-11-10 Novartis Ag Diamino piridino dariniai
AU2017296289A1 (en) 2016-07-12 2019-01-31 Revolution Medicines, Inc. 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors
PL3555070T3 (pl) * 2016-12-19 2023-11-06 Epizyme, Inc. Związki heteroarylowe podstawione aminą jako inhibitory ehmt2 i sposoby ich zastosowania
WO2018136264A1 (en) 2017-01-23 2018-07-26 Revolution Medicines, Inc. Pyridine compounds as allosteric shp2 inhibitors
MX2019008695A (es) 2017-01-23 2019-09-11 Revolution Medicines Inc Compuestos biciclicos como inhibidores alostericos de shp2.
JP2020517618A (ja) 2017-04-21 2020-06-18 エピザイム，インコーポレイティド Ｅｈｍｔ２阻害剤との併用療法
JP7202315B2 (ja) * 2017-05-26 2023-01-11 キャンサー・リサーチ・テクノロジー・リミテッド ベンズイミダゾロン由来のｂｃｌ６阻害剤
CN111315735B (zh) 2017-09-04 2024-03-08 C4医药公司 二氢苯并咪唑酮
TW201930292A (zh) 2017-10-12 2019-08-01 美商銳新醫藥公司 作為變構ｓｈｐ２抑制劑的吡啶、吡嗪和三嗪化合物
JP7254076B2 (ja) * 2017-11-19 2023-04-07 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 置換ヘテロアリール化合物及び使用方法
BR112020009757A2 (pt) 2017-12-15 2020-11-03 Revolution Medicines, Inc. compostos policíclicos como inibidores alostéricos de shp2
US11273158B2 (en) 2018-03-05 2022-03-15 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
AU2019247498A1 (en) 2018-04-05 2020-11-26 Sumitomo Pharma Oncology, Inc. AXL kinase inhibitors and use of the same
MX2020011451A (es) * 2018-05-24 2020-12-07 Astrazeneca Ab Sal de fumarato de 5-((5-metil-2-((3,4,5-trimetilfenil)amino)pirim idin-4-il)amino)-benzo[d]oxazol-2(3h)-ona.
WO2020023910A1 (en) 2018-07-26 2020-01-30 Tolero Pharmaceuticals, Inc. Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
WO2020181232A1 (en) 2019-03-06 2020-09-10 C4 Therapeutics, Inc. Heterocyclic compounds for medical treatment
EP4009974A1 (en) 2019-08-08 2022-06-15 Rigel Pharmaceuticals, Inc. Compounds and method for treating cytokine release syndrome
TW202207934A (zh) 2020-03-27 2022-03-01 瑞典商阿斯特捷利康公司 用於肺遞送的乾粉配製物及使用方法
CN113549018B (zh) * 2020-04-24 2024-02-27 中国药科大学 蛋白激酶抑制剂及其衍生物，制备方法、药物组合物和应用
US20230227484A1 (en) * 2020-05-29 2023-07-20 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. Pyrimidine compound as axl inhibitor
WO2022188735A1 (en) * 2021-03-08 2022-09-15 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as hpk1 inhibitors
CN116178434A (zh) * 2021-11-26 2023-05-30 南京正大天晴制药有限公司 Axl激酶抑制剂的单对甲苯磺酸盐及其晶型
CN116178433A (zh) * 2021-11-26 2023-05-30 南京正大天晴制药有限公司 Axl激酶抑制剂的盐及其制备方法和用途

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
ATE138814T1 (de) 1989-04-28 1996-06-15 Riker Laboratories Inc Inhalationsvorrichtung für trockenpulver
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
ATE107176T1 (de) 1989-12-04 1994-07-15 Searle & Co System zur transdermalen albuterol applikation.
US5364833A (en) 1990-05-09 1994-11-15 Basf Aktiengesellschaft Cyclohexenone oxime ethers, their preparation and their use as herbicides
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5404871A (en) 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
US5327883A (en) 1991-05-20 1994-07-12 Dura Pharmaceuticals, Inc. Apparatus for aerosolizing powdered medicine and process and using
US5492112A (en) 1991-05-20 1996-02-20 Dura Pharmaceuticals, Inc. Dry powder inhaler
US6060069A (en) 1991-05-20 2000-05-09 Dura Pharmaceuticals, Inc. Pulmonary delivery of pharmaceuticals
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
EP0617665B1 (en) 1991-12-18 1999-03-31 Minnesota Mining And Manufacturing Company Multilayered barrier structures
US5320094A (en) 1992-01-10 1994-06-14 The Johns Hopkins University Method of administering insulin
ATE132381T1 (de) 1992-01-29 1996-01-15 Voelkl Franz Ski Ballspielschläger, insbesondere tennisschläger
US5277195A (en) 1992-02-03 1994-01-11 Dura Pharmaceuticals, Inc. Portable spirometer
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
DK0665759T3 (da) 1992-10-19 1999-08-23 Dura Pharma Inc Tørpulverinhalator
US5364838A (en) 1993-01-29 1994-11-15 Miris Medical Corporation Method of administration of insulin
AU6167894A (en) 1993-01-29 1994-08-15 Miris Medical Corporation Intrapulmonary delivery of hormones
US5558085A (en) 1993-01-29 1996-09-24 Aradigm Corporation Intrapulmonary delivery of peptide drugs
US5743250A (en) 1993-01-29 1998-04-28 Aradigm Corporation Insulin delivery enhanced by coached breathing
US5672581A (en) 1993-01-29 1997-09-30 Aradigm Corporation Method of administration of insulin
US6131567A (en) 1993-01-29 2000-10-17 Aradigm Corporation Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
US5661130A (en) 1993-06-24 1997-08-26 The Uab Research Foundation Absorption enhancers for drug administration
US5506203C1 (en) 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
BR9507023A (pt) 1994-03-07 1997-09-23 Inhale Therapeutic Syst Processos para aerossolização de uma dose de insulina para a liberação respiratória de insulina e para preparação de uma composição de insulina e composição de insulina
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5645051A (en) 1995-04-21 1997-07-08 Dura Pharmaceuticals, Inc. Unit dose dry powder inhaler
US5622166A (en) 1995-04-24 1997-04-22 Dura Pharmaceuticals, Inc. Dry powder inhaler delivery system
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US5700904A (en) 1995-06-07 1997-12-23 Eli Lilly And Company Preparation of an acylated protein powder
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
ATE261730T1 (de) 1997-12-31 2004-04-15 Univ Kansas Wasserlösliche medikamentenvorstufen tertiärer amine enthaltender medikamente und verfahren zu ihrer herstellung
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
US6241969B1 (en) 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US20020006901A1 (en) 1999-02-05 2002-01-17 Aldo T. Iacono Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
AU2001226029A1 (en) 2000-01-10 2001-07-24 Dura Pharmaceuticals, Inc. Pharmaceutical formulation and method for pulmonary and oral delivery
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
CN1678321A (zh) 2002-07-29 2005-10-05 里格尔药品股份有限公司 用2,4－嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法
EP1656372B1 (en) 2003-07-30 2013-04-10 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
ES2424881T3 (es) 2003-08-15 2013-10-09 Novartis Ag 2,4-Di(fenilamino)-pirimidinas útiles en el tratamiento de enfermedades neoplásicas, trastornos inflamatorios y del sistema inmunitario
WO2006074057A2 (en) 2004-12-30 2006-07-13 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
ATE451381T1 (de) 2005-01-19 2009-12-15 Rigel Pharmaceuticals Inc Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
CA2608367C (en) 2005-06-08 2014-08-19 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US7713987B2 (en) * 2005-12-06 2010-05-11 Rigel Pharmaceuticals, Inc. Pyrimidine-2,4-diamines and their uses
EP2046759A1 (en) * 2006-07-21 2009-04-15 Novartis AG 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors
GB0615619D0 (en) * 2006-08-05 2006-09-13 Astrazeneca Ab Chemical process for preparation of intermediates
DK2089369T3 (da) * 2006-10-19 2011-05-09 Rigel Pharmaceuticals Inc 2,4-pyrimidindiaminderivater som hæmmere af JAK-kinaser til behandling af autoimmune sygdomme
US7947698B2 (en) 2007-03-23 2011-05-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
WO2009063240A1 (en) * 2007-11-16 2009-05-22 Arrow Therapeutics Limited 2,4-diaminopyrimidine derivatives useful as inhibitors of aurora kinase
EP2389372B1 (en) * 2009-01-23 2015-09-09 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
TW201107329A (en) * 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
RU2672100C2 (ru) * 2010-07-28 2018-11-12 Райджел Фармасьютикалз, Инк. Композиции и способы ингибирования пути jak

Also Published As

Publication number Publication date
US20150307515A1 (en) 2015-10-29
SG172885A1 (en) 2011-08-29
US20180265503A1 (en) 2018-09-20
IL214208A (en) 2015-08-31
US20130310364A1 (en) 2013-11-21
EP2389372B1 (en) 2015-09-09
AU2010206683A1 (en) 2011-08-11
HK1183023A1 (en) 2013-12-13
US9248132B2 (en) 2016-02-02
US8524901B2 (en) 2013-09-03
WO2010085684A1 (en) 2010-07-29
EP2389372A1 (en) 2011-11-30
US8563569B2 (en) 2013-10-22
KR101762967B1 (ko) 2017-07-28
SMT201500308B (it) 2016-01-08
EP2565193A1 (en) 2013-03-06
PT2389372E (pt) 2016-01-07
IL214208A0 (en) 2011-08-31
US20140221352A1 (en) 2014-08-07
CN102356075B (zh) 2015-06-10
US20120046245A1 (en) 2012-02-23
JP5802136B2 (ja) 2015-10-28
JP2012515793A (ja) 2012-07-12
US8507675B2 (en) 2013-08-13
AU2010206683B2 (en) 2016-05-05
CA2749217A1 (en) 2010-07-29
US20170137411A1 (en) 2017-05-18
PL2565193T3 (pl) 2014-07-31
SG2014005318A (en) 2014-03-28
ES2473584T3 (es) 2014-07-07
EP2565193B1 (en) 2014-03-19
US10556891B2 (en) 2020-02-11
PE20110924A1 (es) 2011-12-24
BRPI1006942A2 (pt) 2016-04-12
SI2565193T1 (sl) 2014-07-31
EA201190082A1 (ru) 2012-02-28
US20120016131A1 (en) 2012-01-19
HK1163076A1 (zh) 2012-09-07
PT2565193E (pt) 2014-06-05
ES2555491T3 (es) 2016-01-04
HRP20140454T1 (hr) 2014-06-20
HUE026315T2 (en) 2016-06-28
CN102356075A (zh) 2012-02-15
US9084795B2 (en) 2015-07-21
US20120010406A1 (en) 2012-01-12
US8563716B2 (en) 2013-10-22
US8530656B2 (en) 2013-09-10
US8324200B2 (en) 2012-12-04
SMT201400071B (it) 2014-07-07
US9566283B2 (en) 2017-02-14
HRP20151325T1 (hr) 2016-01-01
NZ594323A (en) 2013-05-31
PL2389372T3 (pl) 2016-02-29
US20120010407A1 (en) 2012-01-12
US20140011770A1 (en) 2014-01-09
US10005767B2 (en) 2018-06-26
US20120016122A1 (en) 2012-01-19
PE20150621A1 (es) 2015-05-07
KR20110111496A (ko) 2011-10-11
SI2389372T1 (sl) 2016-02-29
DK2565193T3 (da) 2014-06-16
US20200216431A1 (en) 2020-07-09
US8735400B2 (en) 2014-05-27
CA2749217C (en) 2017-03-21
MX2011007750A (es) 2011-09-29
US20100190770A1 (en) 2010-07-29
EA022802B1 (ru) 2016-03-31

Similar Documents

Publication Publication Date Title
DK2389372T3 (da) Sammensætninger og fremgangsmåder til hæmning af jak-reaktionsvejen
US8993585B2 (en) Cyclic amine substituted pyrimidinediamines as PKC inhibitors
US20220249475A1 (en) Compounds and method for treating cytokine release syndrome